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1. RESUMEN 
 
El objetivo del presente estudio fue vigilar la dinámica clonal de dos años de 
aislados de Staphylococcus aureus resistentes a meticilina (SARM) en un hospital 
ecuatoriano de tercer nivel a través de un estudio con muestras colectadas desde 
Abril 2009 a Diciembre 2010. El genotipaje fue realizado con Multi-Locus Variable-
Number Tandem-Repeat Analysis (MLVA), el tipaje con Staphylococcal Cassette 
Chromosome mec (SCCmec), y los genes (lukS/F-PV) de PVL (Panton Valentine 
Leukocidin) fueron detectados. A partir de 82 pacientes con infecciones por 
SARM, se analizaron 93 aislamientos. En general, al referirnos a los porcentajes 
más altos: 68 (73,1%) fueron USA300 (ST8) y variantes, 72 (77,4%) albergaron 
SCCmec atípicos, y 59 (63,4%) presentaron genes para PVL, incluyendo 44 
(71,0%) de los 62 casos de infecciones en piel y tejidos blandos. 
Fenotípicamente, 30 (44,1%) de 68 aislados ST8 fueron sensibles a todos los 
antibióticos probados, exceptuando cefoxitina. Todos los 93 aislamientos fueron 
resistentes a cefoxitina y no se encontró niveles de resistencia para vancomicina 
o linezolid. La epidemiologia molecular revelo que los aislados ecuatorianos 
pertenecían a 2 grandes complejos clonales: CC8 y CC5. Con 22 de 31 genotipos 
representando al ST8, el CC8 es la población predominante en Ecuador. Sin 
embargo, la dinámica clonal no fue simple. El clon USA300 (ST8) y variantes 
circularon continuamente durante el período de 21 meses pero otros clones como 
el Brasileño (ST239), USA800/pediátrico (ST5), Ibérico (ST247), SLV de ST239 
(ST241), Coreano (ST72) y Alemán del sur/Italiano (ST228) también estuvieron en 
circulación. La circulación esporádica de diferentes ST sugiere una alta diversidad 
de linajes junto con transferencia horizontal de genes apoyada por la variedad 
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encontrada en el SCCmec. Los autores creen que el surgimiento y la sustitución 
clonal de SARM están sucediendo más frecuentemente de lo que se había 
pensado anteriormente. Los resultados de este estudio complementan la 
investigación epidemiológica en la región dado que este estudio es el primer paso 
en la elucidación de las cepas de SARM predominantes de Ecuador y perfiles de 
resistencia. 
 
Palabras clave: Ecuador, MLVA, SARM, PVL, SCCmec, ST8 
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2. ABSTRACT 
 
This study aims to surveil the population dynamics in two-year methicillin-
resistant Staphylococcus aureus (MRSA) isolates in a tertiary Ecuadorian hospital 
through a study with samples collected from April 2009 to December 2010. Multi-
Locus Variable-Number Tandem-Repeat Analysis (MLVA) genotyping and 
Staphylococcal Cassette Chromosome mec (SCCmec) typing were performed and 
Panton Valentine Leukocidin (PVL) genes (lukS/F-PV) were detected. From 82 
patients with MRSA infections, 93 isolates were analyzed. In general, when 
referring to the highest percentages: 68 (73.1%) were USA300 (ST8) and variants, 
72 (77.4%) harbored atypical SCCmec patterns, and 59 (63.4%) presented PVL 
genes, including 44 (71.0%) of the 62 cases of skin and soft tissue infections. 
Phenotypically, 30 (44.1%) of 68 ST8 isolates were susceptible to all proven 
antibiotics, except cefoxitin. All 93 isolates were resistant to cefoxitin and no 
resistance levels were found for vancomycin or linezolid. Molecular epidemiology 
revealed Ecuadorian isolates belonged to 2 major clonal complexes: CC8 and 
CC5. With 22 of 31 genotypes accounting for ST8, CC8 is the predominant MRSA 
population in Ecuador. Nevertheless, clonal dynamics were not simple. USA300 
(ST8) clone and variants circulated continuously during the 21 months period but 
other clones such as Brazilian (ST239), USA800/pediatric (ST5), Iberian (ST247), 
SLV of ST239 (ST241), Korean (ST72), and South-German/Italian (ST228) were 
also in circulation. Sporadic circulation of different ST suggests high linage 
diversity along with horizontal gene transfer supported by the variety found in 
SCCmec. The authors believe MRSA clonal emergence and substitution is 
happening more frequently than previously though. This results complement 
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epidemiological research in the region given that this study is the first step in the 
elucidation of Ecuador’s predominant MRSA strains and resistance profiles. 
 
Key Words: Ecuador, MLVA, MRSA, PVL, SCCmec, ST8  
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This study aims to surveil the population dynamics in two-year methicillin-20 
resistant Staphylococcus aureus (MRSA) isolates in a tertiary Ecuadorian hospital 21 
through a study with samples collected from April 2009 to December 2010. Multi-22 
Locus Variable-Number Tandem-Repeat Analysis (MLVA) genotyping and 23 
Staphylococcal Cassette Chromosome mec (SCCmec) typing were performed and 24 
Panton Valentine Leukocidin (PVL) genes (lukS/F-PV) were detected. From 82 25 
patients with MRSA infections, 93 isolates were analyzed. In general, when 26 
referring to the highest percentages: 68 (73.1%) were USA300 (ST8) and variants, 27 
72 (77.4%) harbored atypical SCCmec patterns, and 59 (63.4%) presented PVL 28 
genes, including 44 (71.0%) of the 62 cases of skin and soft tissue infections. 29 
Phenotypically, 30 (44.1%) of 68 ST8 isolates were susceptible to all proven 30 
antibiotics, except cefoxitin. All 93 isolates were resistant to cefoxitin and no 31 
resistance levels were found for vancomycin or linezolid. Molecular epidemiology 32 
revealed Ecuadorian isolates belonged to 2 major clonal complexes: CC8 and 33 
CC5. With 22 of 31 genotypes accounting for ST8, CC8 is the predominant MRSA 34 
population in Ecuador. Nevertheless, clonal dynamics were not simple. USA300 35 
(ST8) clone and variants circulated continuously during the 21 months period but 36 
other clones such as Brazilian (ST239), USA800/pediatric (ST5), Iberian (ST247), 37 
SLV of ST239 (ST241), Korean (ST72), and South-German/Italian (ST228) were 38 
also in circulation. Sporadic circulation of different ST suggests high linage 39 
diversity along with horizontal gene transfer supported by the variety found in 40 
SCCmec. The authors believe MRSA clonal emergence and substitution is 41 
happening more frequently than previously though. Results complement 42 
epidemiological research in the region given that this study is the first step in the 43 
elucidation of Ecuador’s predominant MRSA strains and resistance profiles.  44 
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Staphylococcus aureus is one of the world’s clinical significant pathogens, and 45 
the subject of intensive investigations in matters of: Virulence, drug resistance 46 
phenotypes, genotypes, and population genetics (1). Investigations are constantly 47 
being focused on methicillin-resistant Staphylococcus aureus (MRSA) population 48 
structure; since an appropriate control of the MRSA problem requires a thorough 49 
understanding of the processes underlying the emergence and spread of its 50 
clones (2). The key step in emergence of MRSA clones is the acquisition of mobile 51 
genetic element Staphylococcal Cassette Chromosome mec (SCCmec) (2, 3), 52 
which carries the mecA gene responsible for methicillin resistance (2, 4). MRSA is 53 
defined by the presence of SCCmec through SCCmec types being recognized by 54 
combinations of mec and ccr gene complexes (5). With at least 11 SCCmec types 55 
(I-XI) reported so far (6), SCCmec typing is considered more reliable than clinical 56 
risk factors and demographic data for molecular epidemiologic analysis (7). Yet, 57 
the development of a high-throughput molecular typing assay (8), based on binary 58 
combinations of the mec class and the ccr allotype, for rapid and simple strain 59 
characterization, as well as a rationalized unifying nomenclature (6, 9), based on 60 
the structure of SCCmec elements, was accomplished just recently. 61 
Understanding the molecular epidemiology and evolution of MRSA offers many 62 
advantages for infection control (8). In S. aureus, infection outcome is generally 63 
determined by strain’s genetic background, virulence factors, along with host 64 
response (10-12). Emerging MRSA clones appear to have acquired traits that 65 
render them more virulent or able to colonize better (12). Acquisition of Panton-66 
Valentine Leukocidin (PVL) genes has been proposed as potentially contributing to 67 
the success of some MRSA linages as well as a significant virulence factor in 68 
particular types of infections (13, 14). Clinically, MRSA which harbor PVL are most 69 
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often associated with pyogenic skin and soft tissue infections (15) but can also 70 
cause life-threatening disease such as necrotizing pneumonia (16). PVL is a 71 
bicomponent leukocidin, encoded by two co-transcribed genes: lukS-PV and lukF-72 
PV (lukS/F-PV) (17), that cause human neutrophil cell death (13) which are the 73 
first line of defense against staphylococcal infections (12). Even though some 74 
animal-model-based investigations have demonstrated PVL’s pathogenicity along 75 
with an epidemiological association between PVL with MRSA lineages and clonal 76 
complexes (14), PVL’s role as a virulence determinant is still under debate (12, 13) 77 
making screening for PVL and MRSA’s genetic background a routine laboratory 78 
procedure. 79 
Clonal analyzes are a trend research topic for they uncover bacteria evolution 80 
and diversification (18). For S. aureus, molecular typing tools enable a clonal 81 
dynamics approach to assess both the substitution phenomenon (diverse clonal 82 
groups becoming more or less prevalent in healthcare centers through time) and 83 
dissemination, while genotyping assays allow the tracing of outbreaks (19). In 84 
MRSA’s evolutionary history, since the analysis of Multi-Locus Sequence Typing 85 
(MLST) data allowed the description and unification of MRSA clonal complexes 86 
(20), disclosing strain’s genetic background has come to be necessary. 87 
Unfortunately MLST relatively high costs made the method not so accessible for 88 
most laboratories (21). In recent years, Multi-Locus Variable-Number Tandem-89 
Repeat Analysis (MLVA) emerged as a more reasonably priced alternative. MLVA 90 
is a genotyping technique, based on the measurement of DNA fragment’s length 91 
that enables epidemiological studies, follow-up of clonal complexes (CCs) 92 
evolution and identification of potential ancestors (1). 93 
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MRSA worldwide dissemination is due to a few successful clones (22) with a 94 
rather specific geographical pattern (23). In Latin America, since 1990, various 95 
epidemic clones have spread with most of the current circulating clones being 96 
related to the five major international clones: NYJ (New York/Japan), Pediatric, 97 
Brazilian, Iberian, and Hungarian (24). As for South America, north cone countries 98 
like Ecuador, Colombia, and Peru have reported a variety of epidemic MRSA 99 
clones and variants circulating. In Ecuador, the highly virulent USA300 lineage has 100 
been established as the almost exclusive CA-like (Community-Associated-like) 101 
clone with the Brazilian clone accounting as the HA-like (Hospital-Associated-like) 102 
clone (25). For Colombia, the Cordobes/Chilean clone is the predominant clone 103 
(24, 26), with the USA300 clone variant (25), variants of the Pediatric clone (24, 104 
27-29), Brazilian clone (25, 30, 31), and Iberian clone also being reported (24). On 105 
the other hand, Peru has identified the HA-MRSA clone USA800 (24, 32). South 106 
cone countries like Chile, Brazil, and Argentina also report several clones. In Chile, 107 
the Cordobes/Chilean clone is the main clone but the Brazilian clone has also 108 
been reported in the country (24, 30). For Brazil, the Brazilian clone and variants 109 
persistently circulate through hospitals (24, 33) followed by other minor clones that 110 
have also been detected, in particular clones related to the NYJ (24, 34), 111 
Hungarian and Pediatric clone (24, 35). For Argentina, the Cordobes/Chilean 112 
clone and variants along with the Brazilian clone are the major clones (30, 31), 113 
coexisting with variants of the Pediatric clone (24).  114 
The aforementioned highly epidemic MRSA clones have been described 115 
owning the following genotypes (11, 25). Brazilian clone: MRSA-ST239-III (an 116 
MRSA sequence type 239 clone bearing SCCmec type III), Chilean/Cordobes 117 
clone: MRSA-ST5-I, USA300 variant: MRSA-ST8-IVc [and its single-locus variant 118 
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(SLV) MRSA-ST923-IV], and MRSA-ST30-IVc clone that has recently been 119 
reported in other South America countries like Uruguay and Brazil (11, 25). 120 
Even though information on MRSA epidemiology in Latin America has 121 
grown (36), data concerning Ecuador is still scarce. Factors as a biased population 122 
sample, and unrepresentative or affected data enforce a challenge in research. In 123 
spite of the defiance, Reyes et al. (25) and Cardenas et al.(19) revealed some 124 
information about Ecuador’s MRSA lineages. Through their research preliminary 125 
information and preclusive laboratory assays, we could hypothesize that strains 126 
similar or related to the USA300/ST8 clone in Ecuador had not been found yet, 127 
along with strains related to other highly epidemic clones in South America. 128 
Consequently, our goal in the present study was to surveil the clonal dynamics of 129 
two-year MRSA isolates in a tertiary Ecuadorian hospital aiming to contribute with 130 
data for a better understanding of the changing characteristics and epidemiology 131 
of MRSA. Despite data being from one hospital, results will complement 132 
epidemiological research on the region given that this study is the first step in the 133 
elucidation of Ecuador’s predominant MRSA strains and resistance profiles.  134 
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MATERIALS AND METHODS 135 
Setting. Vozandes Hospital of Quito, Ecuador recovered S. aureus isolates 136 
from patients attending hospital clinical laboratory facilities. S. aureus isolates 137 
were identified by standard phenotypic methods (mannitol salt agar, catalase test, 138 
and coagulase test) at the species level, and checked for methicillin resistance 139 
(disk diffusion antibiogram with both oxacillin and cefoxitin). All MRSA isolates 140 
were saved for further investigations purposes. One or more isolates per patient 141 
were stored frozen at -20/-80oC in the Vozandes Hospital bacterial collection. For 142 
each patient, demographic data was collected (e.g. name, age, and sex), as was 143 
date and site of isolation. In addition, susceptibility profile encompassing ten 144 
antibiotics (cefoxitin, gentamicin, tetracycline, trimethoprim/sulfamethoxazole, 145 
ciprofloxacin, erythromycin, rifampin, clindamycin, vancomycin, linezolid) was 146 
performed by the Kirby-Bauer Disk Diffusion Susceptibility Test according to the 147 
CLSI guidelines (37). 148 
Study population. All MRSA isolates recovered between April 2009 and 149 
December 2010 were borrowed from the Vozandes Hospital bacterial collection. A 150 
total of ninety three samples isolated from various clinical infections: 62 (66.7%) 151 
skin and soft tissue, 9 (9.7%) tracheal-bronchial, 3 (3.2%) post-surgical wound, 8 152 
(8.6%) blood, 5 (5.4%) bone marrow, and 6 (6.5%) others recovered from 153 
catheters and sterile liquid samples like pleural, synovial, and drainage fluid 154 
(supplementary data). DNA from strains (TrSa214, TrSa152, TrSa150, and 155 
TrSa134) genotyped by fragment analysis were used as controls for MLVA assay.) 156 
DNA from this control strains was kindly donated by Christine Pourcel from París-157 
Sud University. 158 
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MLVA genotyping. MLVA was performed following the methodology of 159 
Pourcel et al. (1) through agarose gel electrophoresis of PCR product. Amplicons 160 
size was measured with the assistance of ImageLab Software V 4.0.1 (Bio-Rad 161 
Laboratories, Hercules, California), and compared with the MLVAbank for 162 
Bacterial Genotyping (http://mlva.u-psud.fr/ [Staphylococcus aureus database]). 163 
MLVA profiles were assigned the nearest sequence type (ST) of its neighbor strain 164 
on Staphylococcus aureus database with criteria of relatedness that could differ 165 
from zero to five VNTR. Population clonal structure was determined using a ten 166 
loci panel as a first-line simplified assay, posteriorly a subsample of ST8 related 167 
isolates was submitted to a second set of four additional loci to increase resolution 168 
(1). MLVA profiles are available for comparison in the MLVAbank for Bacterial 169 
Genotyping (http://mlva.u-psud.fr/mlvav4/genotyping/view.php?b=CBQCA_MRSA/ 170 
[CBQCA_MRSA database]). 171 
SCCmec typing and PVL. S. aureus species, methicillin resistance, and PVL 172 
genes detection were achieved through amplification of nuc, mecA, and lukS/F-PV 173 
(co-presence) genes respectively by a multiplex-PCR assay described previously 174 
(38). SCCmec types were characterized using a PCR based methodology 175 
reported by Chen et al. (8) through an assay that consists of two multiplex panels, 176 
the combination of which results in two targets (mec class, ccr) for each SCCmec 177 
type. 178 
Statistical analysis. The Unweighted Pair Group Method with Arithmetic Mean 179 
(UPGMA) clustering method was run using the categorical coefficient (Hamming’s 180 
distance) using PAST Ver. 2.06 with bootstrap analysis run at 10000 iterations. A 181 
minimum spanning network (MSN) was generated using R Ver. 3.1.2 to allow the 182 
creation of clusters and visual relationships between the isolates. Simpson’s 183 
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diversity index and Hunter-Gaston’s diversity index were calculated using V-DICE 184 
(VNTR DIversity and Confidence Extractor; http://www.hpa-185 
bioinformatics.org.uk/cgi-bin/DICI/DICI.pl, last accessed on August 2015. Null 186 
hypothesis of linkage equilibrium was tested using LIAN (LInkage ANalysis) Ver. 187 
3.7 with Monte-Carlo simulation run at 10000 iterations, 188 
http://guanine.evolbio.mpg.de/cgi-bin/lian/lian.cgi.pl/query, last accessed on 189 
August 2015. Disclaimer. Clinical variables were not included in the analysis, this 190 
being a limiting factor of this study in the interpretation of findings related to 191 
mortality and clinical recovery.  192 
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RESULTS 193 
Genetic relatedness with MLVA. In our local MRSA population, a total of 31 194 
genotypes (Appendix 1) were observed among the 93 isolates (panel 10 loci). 195 
Likewise, 22 genotypes (panel 10 loci) and 31 genotypes (Appendix 2) (panel 14 196 
loci) were observed among 68 ST8 subsample. Population relatedness was as 197 
following: 68 (73.1%) ST8, 13 (14.0%) ST239, 6 (7.5%) ST247, 3 (3.2%) ST5, 1 198 
(1.1%) ST241, 1 (1.1%) ST72, and 1 (1.1%) ST228. 199 
SCCmec typing, antibiotic susceptibilities and PVL. SCCmec typing of 93 200 
isolates identified the presence of four types: 10 (8.8%) isolates harboring 201 
SCCmec type IVh, 5 (5.4%) type IV, 3 (3.2%) type III and 3 (3.2%) type IIIB. 202 
Interestingly, 72 (77.4%) isolates showed an atypical PCR pattern that could not 203 
be fitted into current SCCmec types, representing 18 different variants (Table 1). 204 
Antibiotic susceptibility profiles showed 22 resistance phenotypes (Table 3). 205 
Among 93 cefoxitin resistant isolates, 34 (36.6%) were resistant to tetracycline, 34 206 
(36.6%) to erythromycin, 27 (29.0%) to ciprofloxacin, 22 (23.7%) to gentamicin, 22 207 
(23.7%) to trimethoprim/sulfamethoxazole, 22 (23.7%) to clindamycin, and 21 208 
(22.6%) to rifampin. No resistant isolates were registered for vancomycin and 209 
linezolid (Figure 5). Finally, virulence factor Panton Valentine Leukocidin (PVL) 210 
was detected in 59 (63.4%) isolates.  211 
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DISCUSSION 212 
Epidemiological surveillance of MRSA is complex. Circulating MRSA clones 213 
vary through regions and countries (24) highlighting the need for highly 214 
discriminatory typing tools (2). In our first approximation to MRSA clonal dynamics, 215 
an MLVA approach was performed as a first line assay. By applying MLVA on 93 216 
MRSA, 31 distinct genotypes were obtained with 10 loci. To increase resolution in 217 
our subsample, we further enhanced the assay through the addition of four 218 
additional loci as suggested by Pourcel et al. (1). A rise in genotypes was 219 
observed in the subsample, 22 genotypes obtained with 10 loci to 31 genotypes 220 
obtained with 14 loci, validated how the discriminatory rate of MLVA improved with 221 
the use of more loci. We don’t believe this assures the technique needs the adding 222 
of more loci continuously. Rather, we agree with a thoughtful selection of loci and 223 
primers for the formation of a proper set that can efficiently assign and amplify 224 
every single strain in a population. For S. aureus genotyping, various loci have 225 
been proposed through the years (1, 21, 39) but, there is still no consensus on the 226 
set of VNTR markers. S. aureus intraspecies genetic variability is an attribute to be 227 
taken into consideration for VNTR marker selection if few loci are going to be 228 
considered. Occasions when VNTR amplification does not occur has been 229 
attributed to intraspecies genetic variability. In our population, there were 15 times 230 
in which a locus could not be amplified. It is not a disappointing percentage (1.2%) 231 
when 1302 amplifications were made but as the majority of these events occurred 232 
in locus SA0122, the use of this locus in a single assay is not advisable. We 233 
recommend the more discriminatory loci: SA0122, SA1132, SA0704, SA0311 and 234 
SA0266 for recent evolution event assessment, as well as for short scale 235 
epidemiological studies (Table 2). 236 
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Before MLVA, the best available techniques used to type S. aureus were Multi-237 
Locus Sequence Typing (MLST) and Pulsed-Field Gel Electrophoresis (PFGE). 238 
These techniques, though innovative at the time of their conception, had difficulties 239 
that needed to be assessed. MLST highly conserved sequences have a slow 240 
evolution rate which causes low resolution in recent evolution investigations, also 241 
low resolution is not suitable for short-term epidemiological studies (1). PFGE 242 
allowed the constitution of shared databases but only at a national level (21). 243 
MLVA technology has overcome the above technical difficulties as it has proven to 244 
be as portable as MLST, and more discriminatory than PFGE and MLST (21). 245 
Nonetheless, for complete and accurate epidemiological information on bacterial 246 
strain diversity, genomics are required. The ultimate choice of technology at the 247 
moment is Whole Genome Sequencing (WGS). However WGS requirements 248 
(resources, infrastructure) make the technology not accessible for every study. 249 
MLVA is the best alternative for S. aureus genotyping while Next Generation 250 
Sequencing is not yet easily available, especially in developing countries. MLVA is 251 
a technique that can be performed in a laboratory with basic molecular biology 252 
equipment and in contrast to other fingerprinting methods, it allows the coding of 253 
results as strings of numbers which makes the resulting profiles highly 254 
reproducible and portable between laboratories and countries (1). In this study, 255 
MLVA technology provided an informative basis for monitoring our MRSA 256 
population. MLVA high reproducibility and comparability, along with available on-257 
line genotyping databases [MLVAbank for Bacterial Genotyping (http://mlva.u-258 
psud.fr/)] enabled the query and comparisons of our results. Additionally it allowed 259 
the placement of our genotypic profiles online (http://mlva.u-psud.fr/ 260 
[CBQCA_MRSA database]). By using MLVA, we did not only succeed in 261 
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genotyping our local population, but also contributed with valuable data that will 262 
enable MLVA usage in our region. 263 
To surveil which clones were the most prevalent in our MRSA population, we 264 
performed a cluster of our profiles together with other international MRSA in the 265 
MLVAbank. Cluster analysis revealed our population had genetic relatedness with 266 
7 different ST but as we analyzed ST correlation with SCCmec type, we observed 267 
ST did not harbor only one kind of SCCmec, therefore they could be better 268 
described as linages and clone variants. In Ecuador, the presence of linages such 269 
as USA300 (ST8) and Brazilian (ST239) has been previously reported (25). Now, 270 
in our study we are also reporting the presence of such linages. ST8 is the 271 
predominant linage (73.1%) while ST239 is present in a lower percentage (14.0%) 272 
of our population. Interestingly we found the occurrence of ST5, USA800 linage 273 
(3.2%). USA800 linage, also known as pediatric, has been previously described 274 
circulating in other north cone countries (24, 40) but not yet in Ecuador. Aside the 275 
highly epidemic linages in our region; we are also reporting the presence of other 276 
linages such as ST247, Iberian; ST241, a single locus variant of ST239; ST72, 277 
Korean; and ST228, South-German/Italian. It is important to notice that among 278 
these new circulating linages, Iberian linage (ST247) is present in a higher 279 
percentage (6.5%) than the USA800 linage (3.2%). 280 
Loci data provides a series of possibilities for MRSA. Population structure of 281 
MRSA used in this study can be observed in both a dendrogram and a MSN. A 282 
dendrogram (Figure 1) was built to show the earlier evolutionary history while an 283 
MSN (Figure 3,Figure 4) was built to achieve an adequate representation of recent 284 
evolutionary events as recommended by Feil et al. (1, 18, 41). With 10 loci data 285 
ST of 2 isolates could not be assigned, however when we observed the MSN 286 
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(Figure 3) in which ST unrelated isolates were clustered near ST228 and ST5, we 287 
suspected these isolates belonged to CC5. To achieve the right assignment of 288 
these isolates, a higher resolution was needed. With 14 loci, ST unrelated isolates 289 
were clustered on ST5 (Figure 4). Interestingly, in the ST8 subsample, previously 290 
designated ST8 isolates changed its relatedness. From 68 ST8 isolates, 3 change 291 
to ST241, 1 to ST239, and 64 remained ST8. MSN shows a more realistic model 292 
of the way in which bacterial clones emerge and diversify to form clonal complexes 293 
(18). Clonal complex assignment for each ST was done by literature comparisons. 294 
Using cut value of 0.6, 3 clusters could be observed in the dendrogram (Figure 1) 295 
which are supposed to be equivalent to MLST clonal complexes but in our isolates 296 
ST were assigned to 2 clonal complexes: CC8 and CC5. Interestingly one isolate 297 
was position as an outer group which caused the formation of 3 complexes: ST72 298 
isolate corresponded to CC8 but it did not cluster with it. This outlier may have 299 
been misplaced due to an unequal evolutionary rate, or it could have been that 300 
ST72 is in fact more related to CC5 than to CC8. We also notice MSN positioned 301 
ST72 (Figure 4) near both CC5 and CC8. Our dendrogram showed low bootstrap 302 
values for some branches which may indicate a founder effect, leading to an 303 
overall low phylogenetic diversity of this population, although some limited 304 
horizontal gene transfer could also have played a role in generating these low 305 
bootstrap values. Both concepts are consistent to what would be expected for 306 
bacteria emergence. Also as expected, output data of LIAN (Appendix 3) IAS 307 
=0.2179 show linkage disequilibrium with a P< 1.00 x 10-04 , which fitted with what 308 
was currently known about population genetics of bacteria in general. This data 309 
assures us that homoplasy (the occurrence of genotypes that are identical by state 310 
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but not by descent) is low in our population and shows MRSA following a clonal 311 
model of mutations more than homology. 312 
MRSA typing of our 93 isolates revealed 4 SCCmec types and several (18) 313 
atypical variants circulating (Table 1). This shows some discrepancies as for what 314 
is expected from the local spread of a clone, where most isolates within clones 315 
harbored an identical SCCmec type (2). We could cautiously suspect not local 316 
spread but local emergence along with distinct importations of related isolates, 317 
because even if local acquisition is happening, it may not explain all the variability 318 
observed. Atypical variants may be caused by the dynamic nature of SCCmec 319 
elements in which varibility could be attributed to the oriC envirion. SCCmec is part 320 
of oriC envirion, a region around the oriC where multiple exogenous genes are 321 
accumulated as a result of repeated horizontal gene transfer events, once again 322 
low bootstrap values in the dendrogram (Figure 1) could confirm this suspicion. The 323 
oriC has been given the function of being an extremely active diversifier of the 324 
chromosome which means oriC environ serves as the generator of diversity by 325 
accumulating foreign genes, deleting useless or hazardous ones, and event 326 
inverting large chromosomal fragments across the oriC (42). Another plausible 327 
explanation for SCCmec variability could be the use of Chen et al.(8) 328 
methodology. Chen’s assay allows a high-throughput typing targeting the specific 329 
mec and ccr regions of the isolates in an individual way. This is a fundamental 330 
difference with previous typing schemes which have risk discriminatory power for 331 
convenience by targeting zones located within J regions.  332 
In our atypical variants exist a pattern that has been observed in a similar study 333 
by Basset et al. (2) whom reported our pattern NT16 as U7. Other studies have 334 
also reported atypical SCCmec in MRSA, however these patterns are more 335 
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common in other staphylococcal species (2, 8, 43). Due to the presence of atypical 336 
variants with different combinations of mec and ccr complexes, we believed in 337 
using ccr and mec complexes as an adequate nomenclature of SCCmec element. 338 
Several nomenclatures have been proposed through the years but a consensus 339 
among all staphylococcal researchers has not been reached. Interestingly, 73 340 
(78%) of our variants carried ccrC. We believe this may have various explanations. 341 
1. It may be due to ccr recombinase being carried in other unknown mobile genetic 342 
element rather than being inside SCCmec. 2. The recombinase might be outside 343 
of SCCmec but inside SCCHg. 3. It is part of SCCmec. Further studies will be 344 
needed to define if atypical variants should be considered new cassettes. But for 345 
epidemiological purposes, mec and ccr assignment may be enough (43). If we 346 
interpreted our atypical SCCmec patterns with the original definition of SCCmec 347 
type being defined by the binary combination of the ccr-gene complex and the 348 
class of mec-gene complex, we could reduce the reported variants to 2 (NT10, 349 
NT12). At the present, 11 SCCmec types are registered according to the IWG-350 
SCC (http://www.sccmec.org/Pages/SCC_HomeEN.htmL, last accessed 15 March 351 
2015) but they do not exclude the finding of more variants: “more types are 352 
expected to be found in the future”. In addition, there were 4 occasions in which 353 
the mec type could not be amplified. Another attention-grabbing point in our results 354 
was the absence of HA-cassettes (I and II) and recently described cassettes (VI-355 
XI). Absence of these previously described SCCmec types could mean sampling 356 
limitations or even primer mutations, mutations in specific primer regions that did 357 
not allow us to genotype 93 isolates. 358 
The percentage of resistance in 93 isolates remained the same though the years 359 
(Figure 5) because independent resistance levels for each antibiotic did not reveal 360 
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much information. To assess resistance in a more realistic manner we analyzed 361 
resistance phenotypes. When we correlated them together with ST, relationships 362 
were noticed. ST239 strains harbored highly resistant phenotypes while ST8 363 
harbored highly susceptible phenotypes (Table 3). 364 
More than half of our isolates 59 (63.4%) presented PVL genes, including 365 
44 (71.0%) of the 62 cases of skin and soft tissue infection isolates. In South 366 
America, the presence PVL has been reported among MRSA populations (24). 367 
Our high rate of PVL positivity could be attributed to the majority of isolates being 368 
from skin and soft tissue infections and being related to the USA300 clone (ST8). 369 
Both skin and soft tissue (15) and ST8 have been associated with PVL positivity 370 
(11). We found important to say that an increased in virulence does not imply a 371 
bad clinical outcome. In early reports PVL was alleged it to be a deadly toxin, 372 
nevertheless nowadays those characteristics have been refuted in several papers 373 
(11, 14). What it most, in recent studies PVL has been related to favorable and 374 
improved clinical outcomes. In what is most in our analysis of resistance 375 
phenotypes together with PVL, a relationship virulence-resistance was noticed. 376 
Highly resistant ST239 strains did not carry PVL while ST8 highly susceptible 377 
strains carry PVL. Even though some exceptions can be observed, patterns are 378 
much clearer.  379 
In conclusion, this study aimed to understand the clonal dynamics of a 93 380 
MRSA population thought the surveillance of clones and SCCmec types. CC8 is 381 
Ecuador predominant population, with USA300/ST8 linage being in constant 382 
circulation. Constant genetic change at a local or short scale could be suspect. 383 
Clone emergence along with acquisition of SCCmec is happening. Although 384 
USA300/ST8 continues to be the highly epidemic clone reported for the country, 385 
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new circulating linages: Iberian/ST247, ST241/SLV of ST239, Korean/ST72, and 386 
South-German/Italian/ST228, suggest importations. Because of the relationship 387 
between ST linages and resistance phenotypes, monitoring MRSA evolution and 388 
distribution supports the use of effective measures against the most prevalent 389 
clones in each local region. More than 50 years later eradication is still far ahead 390 
us as MRSA continues to be one of the most common hospital pathogens 391 
worldwide.  392 
24 
 
Availability of supporting data 393 
The data set supporting the results of this article is included as an additional 394 
file. MLVA profiles are available for comparison in the MLVAbank for Bacterial 395 
Genotyping (http://mlva.u-psud.fr/ [CBQCA_MRSA database]). 396 
Competing interests 397 
All authors report no conﬂicts of interest relevant to this article. 398 
Authors’ contributions 399 
All authors equally participated in designing the study, acquisition, analysis 400 
and interpretation of data. All authors read and approved the final manuscript. 401 
ACKNOWLEDGEMENTS 402 
Genotyping assays were supported by: Pontificia Universidad Católica del 403 
Ecuador through Facultad de Ciencias Exactas y Naturales, Escuela de Ciencias 404 
Biológicas equipment, and Facultad de Medicina, Project K13106. Zurita&Zurita 405 
Laboratorios Project MIC-006. We thank the administration of Hospital Vozandes-406 
Quito for strains. We thank Christine Pourcel from Paris Sud University for the kind 407 
gift of control DNA.  408 
25 
 
REFERENCES 409 
1. Pourcel C, Hormigos K, Onteniente L, Sakwinska O, Deurenberg RH, 410 
Vergnaud G. 2009. Improved Multiple-Locus Variable-Number Tandem-411 
Repeat Assay for Staphylococcus aureus Genotyping, Providing a Highly 412 
Informative Technique Together with Strong Phylogenetic Value. Journal of 413 
Clinical Microbiology 47:3121-3128. 414 
2. Basset P, Senn L, Vogel V, Zanetti G, Blanc DS. 2010. Diversity of 415 
staphylococcal cassette chromosome mec elements in predominant 416 
methicillin-resistant Staphylococcus aureus clones in a small geographic 417 
area. Antimicrobial agents and chemotherapy 54:4589-4595. 418 
3. Katayama Y, Ito T, Hiramatsu K. 2000. A new class of genetic element, 419 
staphylococcus cassette chromosome mec, encodes methicillin resistance 420 
in Staphylococcus aureus. Antimicrobial agents and chemotherapy 421 
44:1549-1555. 422 
4. Matsuhashi M, Song MD, Ishino F, Wachi M, Doi M, Inoue M, Ubukata 423 
K, Yamashita N, Konno M. 1986. Molecular cloning of the gene of a 424 
penicillin-binding protein supposed to cause high resistance to beta-lactam 425 
antibiotics in Staphylococcus aureus. J Bacteriol 167:975-980. 426 
5. Hiramatsu K, Cui L, Kuroda M, Ito T. 2001. The emergence and evolution 427 
of methicillin-resistant Staphylococcus aureus. Trends Microbiol 9:486-493. 428 
6. Ito T, K. , Hiramatsu DC, Oliveira H, de Lencastre KY, Zhang H, Westh 429 
F, O’Brien PM, Giffard D, Coleman FC, Tenover S, Boyle-Vavra RL, 430 
Skov MC, Enright B, Kreiswirth KS, Ko H, Grundmann F, Laurent JE, 431 
Sollid AM, Kearns R, Goering JF, John R, Daum aBS. 2009. 432 
Classification of staphylococcal cassette chromosome mec (SCCmec): 433 
26 
 
guidelines for reporting novel SCCmec elements. Antimicrobial agents and 434 
chemotherapy 53:4961-4967. 435 
7. Kuo SC, Chiang MC, Lee WS, Chen LY, Wu HS, Yu KW, Fung CP, 436 
Wang FD. 2012. Comparison of microbiological and clinical characteristics 437 
based on SCCmec typing in patients with community-onset meticillin-438 
resistant Staphylococcus aureus (MRSA) bacteraemia. Int J Antimicrob 439 
Agents 39:22-26. 440 
8. Chen L, Mediavilla JR, Oliveira DC, Willey BM, de Lencastre H, 441 
Kreiswirth BN. 2009. Multiplex real-time PCR for rapid Staphylococcal 442 
cassette chromosome mec typing. J Clin Microbiol 47:3692-3706. 443 
9. Chongtrakool P, Ito T, Ma XX, Kondo Y, Trakulsomboon S, 444 
Tiensasitorn C, Jamklang M, Chavalit T, Song JH, Hiramatsu K. 2006. 445 
Staphylococcal cassette chromosome mec (SCCmec) typing of methicillin-446 
resistant Staphylococcus aureus strains isolated in 11 Asian countries: a 447 
proposal for a new nomenclature for SCCmec elements. Antimicrobial 448 
agents and chemotherapy 50:1001-1012. 449 
10. Ganga R, Riederer K, Sharma M, Fakih MG, Johnson LB, Shemes S, 450 
Khatib R. 2009. Role of SCCmec Type in Outcome of Staphylococcus 451 
aureus Bacteremia in a Single Medical Center. Journal of Clinical 452 
Microbiology 47:590-595. 453 
11. Portillo BC, Moreno JE, Yomayusa N, Álvarez CA, Cardozo BEC, Pérez 454 
JAE, Díaz PL, Ibañez M, Mendez-Alvarez S, Leal AL, Gómez NV. 2013. 455 
Molecular epidemiology and characterization of virulence genes of 456 
community-acquired and hospital-acquired methicillin-resistant 457 
27 
 
Staphylococcus aureus isolates in Colombia. International Journal of 458 
Infectious Diseases 17:e744-e749. 459 
12. Otto M. 2012. MRSA virulence and spread. Cell Microbiol 14:1513-1521. 460 
13. Löffler B, Hussain M, Grundmeier M, Brück M, Holzinger D, Varga G, 461 
Roth J, Kahl BC, Proctor RA, Peters G. 2010. Staphylococcus aureus 462 
Panton-Valentine Leukocidin Is a Very Potent Cytotoxic Factor for Human 463 
Neutrophils. PLoS Pathog 6:e1000715. 464 
14. Boakes E, Kearns AM, Badiou C, Lina G, Hill RL, Ellington MJ. 2012. 465 
Do differences in Panton-Valentine leukocidin production among 466 
international methicillin-resistant Staphylococcus aureus clones affect 467 
disease presentation and severity? J Clin Microbiol 50:1773-1776. 468 
15. Lina G, Piemont Y, Godail-Gamot F, Bes M, Peter MO, Gauduchon V, 469 
Vandenesch F, Etienne J. 1999. Involvement of Panton-Valentine 470 
leukocidin-producing Staphylococcus aureus in primary skin infections and 471 
pneumonia. Clin Infect Dis 29:1128-1132. 472 
16. Gillet Y, Issartel B, Vanhems P, Fournet JC, Lina G, Bes M, 473 
Vandenesch F, Piemont Y, Brousse N, Floret D, Etienne J. 2002. 474 
Association between Staphylococcus aureus strains carrying gene for 475 
Panton-Valentine leukocidin and highly lethal necrotising pneumonia in 476 
young immunocompetent patients. Lancet 359:753-759. 477 
17. McClure JA, Conly JM, Lau V, Elsayed S, Louie T, Hutchins W, Zhang 478 
K. 2006. Novel multiplex PCR assay for detection of the staphylococcal 479 
virulence marker Panton-Valentine leukocidin genes and simultaneous 480 
discrimination of methicillin-susceptible from -resistant staphylococci. J Clin 481 
Microbiol 44:1141-1144. 482 
28 
 
18. Feil EJ, Enright MC. 2004. Analyses of clonality and the evolution of 483 
bacterial pathogens. Curr Opin Microbiol 7:308-313. 484 
19. Cardenas PA, Alarcon M, Narvaez I, Salazar R, Falconi G, Espinel M, 485 
Trueba G. 2013. Staphylococcus aureus outbreak in the intensive care unit 486 
of the largest public hospital in Quito, Ecuador. Int Microbiol 16:81-86. 487 
20. Enright MC, Day NPJ, Davies CE, Peacock SJ, Spratt BG. 2000. 488 
Multilocus Sequence Typing for Characterization of Methicillin-Resistant 489 
and Methicillin-Susceptible Clones of Staphylococcus aureus. Journal of 490 
Clinical Microbiology 38:1008-1015. 491 
21. Schouls LM, Spalburg EC, van Luit M, Huijsdens XW, Pluister GN, van 492 
Santen-Verheuvel MG, van der Heide HGJ, Grundmann H, Heck MEOC, 493 
de Neeling AJ. 2009. Multiple-Locus Variable Number Tandem Repeat 494 
Analysis of Staphylococcus Aureus: Comparison with Pulsed-Field Gel 495 
Electrophoresis and spa-Typing. PLoS ONE 4:e5082. 496 
22. Nubel U, Roumagnac P, Feldkamp M, Song JH, Ko KS, Huang YC, 497 
Coombs G, Ip M, Westh H, Skov R, Struelens MJ, Goering RV, 498 
Strommenger B, Weller A, Witte W, Achtman M. 2008. Frequent 499 
emergence and limited geographic dispersal of methicillin-resistant 500 
Staphylococcus aureus. Proc Natl Acad Sci U S A 105:14130-14135. 501 
23. Enright MC, Robinson DA, Randle G, Feil EJ, Grundmann H, Spratt 502 
BG. 2002. The evolutionary history of methicillin-resistant Staphylococcus 503 
aureus (MRSA). Proc Natl Acad Sci U S A 99:7687-7692. 504 
24. Rodriguez-Noriega E, Seas C, Guzman-Blanco M, Mejia C, Alvarez C, 505 
Bavestrello L, Zurita J, Labarca J, Luna CM, Salles MJ, Gotuzzo E. 506 
29 
 
2010. Evolution of methicillin-resistant Staphylococcus aureus clones in 507 
Latin America. Int J Infect Dis 14:e560-566. 508 
25. Reyes J, Rincon S, Diaz L, Panesso D, Contreras GA, Zurita J, Carrillo 509 
C, Rizzi A, Guzman M, Adachi J, Chowdhury S, Murray BE, Arias CA. 510 
2009. Dissemination of methicillin-resistant Staphylococcus aureus USA300 511 
sequence type 8 lineage in Latin America. Clin Infect Dis 49:1861-1867. 512 
26. Espinal P, Raciny M, Gaitan S, A. Mo. 2008. First detection of Chilean 513 
clone in clinical isolates of methicillin-resistant Staphylococcus aureus in 514 
the Colombian–Caribbean region.  18th European Congress of Clinical 515 
Microbiology and Infectious Diseases (ECCMID), Barcelona, Spain, 19–22 516 
April. 517 
27. Gomes AR, Sanches IS, Aires de Sousa M, Castaneda E, de Lencastre 518 
H. 2001. Molecular epidemiology of methicillin-resistant Staphylococcus 519 
aureus in Colombian hospitals: dominance of a single unique multidrug-520 
resistant clone. Microb Drug Resist 7:23-32. 521 
28. Buitrago G, Cortes JA, Castillo JS, Leal AL, Sanchez R, CA. A. 2008. 522 
Methicillin-resistant Staphylococcus aureus. Community-acquired 523 
phenotype spread in hospitals in Bogota´, Colombia. Clin Microbiol Infect 524 
14:S411. 525 
29. Cruz C, Moreno J, Renzoni A, Hidalgo M, Reyes J, Schrenzel J, Lew D, 526 
Castaneda E, Arias CA. 2005. Tracking methicillin-resistant 527 
Staphylococcus aureus clones in Colombian hospitals over 7 years (1996-528 
2003): emergence of a new dominant clone. Int J Antimicrob Agents 529 
26:457-462. 530 
30 
 
30. Aires de Sousa M, Miragaia M, Santos Sanches I, Ávila S, Adamson I, 531 
Casagrande ST, Brandileone MCC, Palacio R, Dell'Acqua L, Hortal M, 532 
Camou T, Rossi A, Velazquez-Meza ME, Echaniz-Aviles G, Solorzano-533 
Santos F, Heitmann I, de Lencastre H. 2001. Three-Year Assessment of 534 
Methicillin-Resistant Staphylococcus aureus Clones in Latin America from 535 
1996 to 1998. J Clin Microbiol 39:2197-2205. 536 
31. Sola C, Gribaudo G, Vindel A, Patrito L, Bocco JL. 2002. Identification of 537 
a novel methicillin-resistant Staphylococcus aureus epidemic clone in 538 
Cordoba, Argentina, involved in nosocomial infections. J Clin Microbiol 539 
40:1427-1435. 540 
32. Goering RV, Shawar RM, Scangarella NE, O'Hara FP, Amrine-Madsen 541 
H, West JM, Dalessandro M, Becker JA, Walsh SL, Miller LA, van Horn 542 
SF, Thomas ES, Twynholm ME. 2008. Molecular epidemiology of 543 
methicillin-resistant and methicillin-susceptible Staphylococcus aureus 544 
isolates from global clinical trials. J Clin Microbiol 46:2842-2847. 545 
33. Sader HS, Pignatari AC, Hollis RJ, Jones RN. 1994. Evaluation of 546 
interhospital spread of methicillin-resistant Staphylococcus aureus in Sao 547 
Paulo, Brazil, using pulsed-field gel electrophoresis of chromosomal DNA. 548 
Infect Control Hosp Epidemiol 15:320-323. 549 
34. Melo MC, Silva-Carvalho MC, Ferreira RL, Coelho LR, Souza RR, Gobbi 550 
CN, Rozenbaum R, Solari CA, Ferreira-Carvalho BT, Figueiredo AM. 551 
2004. Detection and molecular characterization of a gentamicin-susceptible, 552 
methicillin-resistant Staphylococcus aureus (MRSA) clone in Rio de Janeiro 553 
that resembles the New York/Japanese clone. J Hosp Infect 58:276-285. 554 
31 
 
35. Vivoni AM, Diep BA, de Gouveia Magalhaes AC, Santos KR, Riley LW, 555 
Sensabaugh GF, Moreira BM. 2006. Clonal composition of 556 
Staphylococcus aureus isolates at a Brazilian university hospital: 557 
identification of international circulating lineages. J Clin Microbiol 44:1686-558 
1691. 559 
36. Mejia C, Zurita J, Guzman-Blanco M. 2010. Epidemiology and 560 
surveillance of methicillin-resistant Staphylococcus aureus in Latin America. 561 
Braz J Infect Dis 14 Suppl 2:S79-86. 562 
37. CLSI. 2010. Surveillance for Methicillin-Resistant Staphylococcus aureus: 563 
Principles, Practices, and Challenges; A Report. Wayne, PA. 564 
38. Reyes A. 2009. PCR multiplex para la identificacion de los genes luk-S y 565 
luk-F codificantes del marcador Leucocidina Valentine Panton, simultanea 566 
a la detección de resistencia a meticilina en muestras de bacteremias 567 
causadas por Staphylococcus aureus. . Ingenieria en Biotecnologia. 568 
Escuela Politecnica del Ejercito  569 
39. Sobral D, Schwarz S, Bergonier D, Brisabois A, Fessler AT, Gilbert FB, 570 
Kadlec K, Lebeau B, Loisy-Hamon F, Treilles M, Pourcel C, Vergnaud 571 
G. 2012. High throughput multiple locus variable number of tandem repeat 572 
analysis (MLVA) of Staphylococcus aureus from human, animal and food 573 
sources. PLoS One 7:e33967. 574 
40. Teixeira MM, Araújo MC, Silva-Carvalho MC, Beltrame CO, Oliveira C, 575 
Figueiredo AMS, Oliveira AG. 2012. Emergence of clonal complex 5 576 
(CC5) methicillin-resistant Staphylococcus aureus (MRSA) isolates 577 
susceptible to trimethoprim-sulfamethoxazole in a Brazilian hospital. 578 
Brazilian Journal of Medical and Biological Research 45:637-643. 579 
32 
 
41. Feil EJ, Li BC, Aanensen DM, Hanage WP, Spratt BG. 2004. eBURST: 580 
inferring patterns of evolutionary descent among clusters of related 581 
bacterial genotypes from multilocus sequence typing data. J Bacteriol 582 
186:1518-1530. 583 
42. Hiramatsu K, Ito T, Tsubakishita S, Sasaki T, Takeuchi F, Morimoto Y, 584 
Katayama Y, Matsuo M, Kuwahara-Arai K, Hishinuma T, Baba T. 2013. 585 
Genomic Basis for Methicillin Resistance in Staphylococcus aureus. Infect 586 
Chemother 45:117-136. 587 
43. Kondo Y, Ito T, Ma XX, Watanabe S, Kreiswirth BN, Etienne J, 588 
Hiramatsu K. 2007. Combination of multiplex PCRs for staphylococcal 589 
cassette chromosome mec type assignment: rapid identification system for 590 
mec, ccr, and major differences in junkyard regions. Antimicrobial agents 591 
and chemotherapy 51:264-274. 592 
593 
33 
 
Tables.  
Table 1. SCCmec patterns found in 93 MRSA. 
Varianta No. of isolates ccr type(s) mec class(es)b 
III 3 3 A 
IIIB 3 3,5 A 
IV 5 2 B 
IVh 10 2,5 B 
NT1 2 2,3 A 
NT2 3 2,3,4,5 A 
NT3 2 2,3,5 A 
NT4 1 2 A,B 
NT5 3 2,3 A,B 
NT6 1 2,5 A,B 
NT7 1 3,5 A,B 
NT8 8 2,3,5 A,B 
NT9 4 2,3 B 
NT10 1 3 B 
NT11 5 3,5 B 
NT12 2 5 B 
NT13 1 1,2,5 B 
NT14 2 2,3,4,5 B 
NT15 31 2,3,5 B 
NT16 1 2 - 
NT17 3 2,3,5 - 
NT18 1 3,5 - 
a, NT stands for Non-Typable. 
b, - no amplification could be obtained.  
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Table 2. Diversity indexes for VNTR data of 93 MRSA. 
Locus Ka max(pi)b 
Simpson’s diversity index Hunter-Gaston’s diversity index 
Diversity Indexc Confidence Intervald Diversity Indexc Confidence Intervald 
SA0122/24_01 7 0.567 0.631 0.540 - 0.722 0.637 0.546 - 0.728 
SA1425 9 0.567 0.618 0.530 - 0.706 0.625 0.537 - 0.713 
SA1132/63_01 6 0.536 0.607 0.540 - 0.674 0.614 0.546 - 0.681 
SA0704/67_01 6 0.598 0.586 0.495 - 0.676 0.592 0.501 - 0.682 
SA0906 6 0.639 0.534 0.440 - 0.628 0.540 0.445 - 0.634 
SA1213 5 0.680 0.485 0.387 - 0.584 0.491 0.392 - 0.589 
SA0311 5 0.711 0.441 0.344 - 0.538 0.446 0.349 - 0.543 
SA1756 3 0.763 0.366 0.274 - 0.459 0.370 0.278 - 0.463 
SA0266/81_01 5 0.825 0.305 0.193 - 0.417 0.308 0.196 - 0.420 
SA1194 4 0.887 0.208 0.103 - 0.313 0.210 0.105 - 0.315 
SA1729 6 0.907 0.175 0.073 - 0.277 0.177 0.075 - 0.279 
SA2039 4 0.907 0.172 0.073 - 0.270 0.173 0.075 - 0.271 
SA1291 4 0.928 0.136 0.045 - 0.228 0.138 0.046 - 0.229 
SA1866 2 0.990 0.020 0.000 - 0.060 0.021 0.000 - 0.060 
a, K = Number of different repeats present at this locus in this sample set. 
b, max(pi) = Fraction of samples that have the most frequent repeat number in this 
locus (range 0.0 to 1.0). 
c,Diversity Index (for VNTR data)= A measure of the variation of the number of 
repeats at each locus. Ranges from 0.0 (no diversity) to 1.0 (complete diversity). 
d, Confidence Interval = Precision of the Diversity Index, expressed as 95% upper 
& lower boundaries.  
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Table 3. Resistance phenotypes found in 93 MRSA. 
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a, P stands for Phenotype. 
b, gentamicin (GEN), tetracycline (TET), trimethoprim-sulfamethoxazole (SXT), 
ciprofloxacin (CIP), erythromycin (ERY), rifampin (RIF), clindamycin (CLI) 
vancomycin (VAN) and linezolid (LZD) not shown. 
S/R missing data or inconclusive results. 
c, CC stands for clonal complex.  
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Figures. 
 
Figure 1. Unrooted dendogram with UPGMA for 10 loci data of 93 MRSA. 
Coph. Corr.: 0.9534. Cut value at 0.6 corresponds to MLST clonal complex. Color code is done according to 
clonal complex whereas clustering is done for displayed loci data. Clonal complex, Relatedness, Distance, 
and Strain id are shown. Cluster bootstrap values are shown for main clusters. 
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Figure 2. Two-year clonal dynamics of 93 MRSA. 
Colors code is based on ST relatedness by MLVA. Each dot represents the 
occurrence of bacteria during the 21 month period. 
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Figure 3. Population snapshot using minimum spanning network for 10 loci data of 
93 MRSA. 
Colors used are based on ST relatedness by MLVA. Each circle represents a 
genotype and its clones, and its size is proportional to the number of isolates 
assigned. A logarithmic scale was used when drawing branches. The thicker 
branches link genotypes differing by only one allele, and the thinner branches link 
genotypes differing by more than one allele. 
39 
 
 
Figure 4. A. Minimum spanning network representation with 10 loci data for 68 
ST8 MRSA isolates clustering. B. Minimum spanning network representation with 
14 loci data for 68 ST8 MRSA isolates clustering. 
Colors used are based on ST relatedness by MLVA. Each circle represents a 
genotype and its clones, and its size is proportional to the number of isolates 
assigned. A logarithmic scale was used when drawing branches. The thicker 
branches link genotypes differing by only one allele, and the thinner branches link 
genotypes differing by more than one allele. 
  
40 
 
 
0
10
20
30
40
50
60
FOX TET ERY CIP GEN SXT CLI RIF VAN LZD
34
20 18
15 13 13 12 12
0 0
54
14 16
12
9 9 10 9
0 0
C
a
s
e
s
Antibiotics
2009
2010
 
Figure 5. Two year antibiotic resistance levels of 93 MRSA. 
Cefoxitin (FOX), tetracycline (TET), erythromycin (ERY), ciprofloxacin (CIP), 
Gentamicin (GEN), trimethoprim-sulfamethoxazole (SXT), clindamycin (CLI), 
rifampin (RIF), vancomycin (VAN) and linezolid (LZD). 
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1. APPENDIX 
Appendix 1. Genotypes with 10 loci MLVA of 93 MRSA. 
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ST239 G1 6 5 3 2 2 3 1 1 3 3 
ST8 G2 10 5 2 6 1 3 1 1 3 3 
ST8 G3 7 5 2 6 1 3 1 1 3 3 
X G4 10 4 1 4 2 7 4 3 3 3 
ST247 G5 11 5 2 6.5 1 3 1 1 3 3 
ST8 G6 9 5 2 6.5 1 3 1 1 3 3 
ST8 G7 10 5 3 6 2 3 1 1 3 3 
ST8 G8 9 5 2 6 1 3 1 1 3 3 
ST228 G9 10 5 3 4 7 5 4 3 3 3 
X G10 10 4 1 4 3 7 4 3 3 3 
ST8 G11 10 4 2 6 2 3 1 1 3 3 
ST8 G12 10 6 2 6 1 3 1 1 3 3 
ST8 G13 10 5 3 2 2 3 1 1 3 3 
ST247 G14 11 5 2 6 3 3 1 1 3 3 
ST8 G15 10 5 2 6 2 3 1 1 3 3 
ST8 G16 10 5 2 6 3 3 1 1 3 3 
ST239 G17 6 5 3 2 3 3 1 1 3 2 
ST8 G18 9 5 2 6 2 5 1 1 3 3 
ST8 G19 11 5 2 6 2 3 1 1 3 3 
ST8 G20 10 4 2 6 1 3 1 1 3 3 
ST8 G21 9 5 2 6 1 7 1 1 3 3 
ST8 G22 10 5 2 6 1 7 1 1 3 3 
ST239 G23 5 5 3 2 2 3 1 1 3 3 
ST8 G24 5 5 2 6 1 3 1 1 3 3 
ST8 G25 10 3 2 6 2 3 1 1 3 3 
ST8 G26 9 4 2 6 2 3 1 1 3 3 
ST8 G27 10 5 2 4 1 3 1 1 3 2 
ST247 G28 11 5 2 6 1 3 1 1 3 3 
ST5 G29 9 6.5 3 4 7.5 3 4 5 3 3 
ST8 G30 10 5 2 6 1 3 1 1 3 2 
ST8 G31 10 5 2 3 1 3 1 1 3 3 
ST8 G32 10 5 2 6 3 3 1 1 3 2 
ST30 G33 7 4 3 3 3 5 2 4 2 4 
ST5 G34 10 6 3 4 7 7 4 5 3 3 
ST45 G35 9 6 5.5 5 2 8 1 5 3 1 
a, X isolates that could not be related to any nearest ST 
b, G32, 33, 34, and 35 correspond to control strains 
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Appendix 2. Genotypes with 14 loci MLVA of ST subsample (68 MRSA). 
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ST8 G1 10 5 2 6 2 1 3 3 1 3 1 2 3 3 
ST8 G2 7 5 2 6 2 1 3 3 1 3 1 2 3 3 
ST8 G3 9 5 2 6.5 2 1 3 3 1 3 1 2 3 3 
ST8 G4 10 5 3 6 3 2 3 3 1 3 1 2 3 3 
ST8 G5 9 5 2 6 2 1 3 3 1 3 1 2 3 3 
ST8 G6 10 4 2 6 2 2 3 3 1 3 1 2 3 3 
ST8 G7 10 6 2 6 2 1 3 3 1 3 1 2 3 3 
ST8 G8 10 5 2 6 2 2 3 3 1 3 1 2 3 3 
ST8 G9 10 5 2 6 2 3 3 3 1 3 1 2 3 3 
ST8 G10 9 5 2 6 1 2 5 3 1 4 1 2 3 3 
ST8 G11 10 5 2 6 2 2 3 3 1 1 1 2 3 3 
ST8 G12 11 5 2 6 2 2 3 3 1 3 1 2 3 3 
ST8 G13 10 4 2 6 2 1 3 3 1 3 1 2 3 3 
ST8 G14 9 5 2 6 2 1 7 3 1 3 1 2 3 3 
ST8 G15 10 5 2 6 3 2 3 3 1 3 1 2 3 3 
ST8 G16 10 5 2 6 2.5 1 7 3 1 3 1 2 3 3 
ST8 G17 10 5 2 6 2 2 3 5.5 1 3.5 1 2 3 3 
ST8 G18 5 5 2 6 2 1 3 3 1 3.5 1 2 3 3 
ST8 G19 10 5 2 6 2 1 3 3 1 3.5 1 2 3 3 
ST8 G20 10 3 2 6 2 2 3 3 1 3 1 2 3 3 
ST8 G21 10 5 2 6 1 1 3 3 1 3 1 2 3 3 
ST8 G22 9 4 2 6 2 2 3 3 1 3.5 1 2 3 3 
ST8 G23 10 5 2 4 2 1 3 3 1 4 1 2 3 2 
ST8 G24 10 5 2 6 2 1 3 3 1 4 1 2 3 3 
ST8 G25 10 5 2 6 2 1 3 3 1 5 1 2 3 3 
ST8 G26 10 4 2 6 1 1 3 3 1 3 1 2 3 3 
ST8 G27 10 5 2 6 2 1 3 3 1 3 1 2 3 2 
ST8 G28 10 5 2 6 2 1 3 3 1 3.5 1 2 3 2 
ST8 G29 9 5 2 6 1 1 3 3 1 1 1 2 3 3 
ST8 G30 10 5 2 6 3 1 3 3 1 3 1 2 3 3 
ST8 G31 10 5 2 3 2 1 3 3 1 3 1 2 3 3 
ST8 G32 10 5 2 6 2 3 3 3 1 3 1 2 3 2 
a, G32 correspond to control strain.  
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Appendix 3. LIAN Output data for 93 MRSA isolates 
Summary Statistics 
VD 5.2214 
Ve 1.7635 
IA
S 0.2179 
Testing Null Hypothesis (H0: VD = Ve) 
Monte Carlo (10000 resamplings) 
Var(VD) 0.0219 
P < 1.00 x 10-04 
L 2.0248 
Genetic Diversity 
Mean genetic diversity (H): 0.3314 +/- 0.0709  
Genetic diversity at individual loci ordered left to right: 
h1 0.6372 
h2 0.3082 
h3 0.4457 
h4 0.5917 
h5 0.6136 
h6 0.2098 
h7 0.1377 
h8 0.1765 
h9 0.0206 
h10 0.1733 
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sponsibility of authors to provide, in the Acknowledgments
section, a general statement disclosing financial or other rela-
tionships that are relevant to the study. Examples of potentially
conflicting interests that should be disclosed include relation-
ships thatmight detract from an author’s objectivity in presen-
tation of study results and interests whose value would be en-
hanced by the results presented. All funding sources for the
project, institutional and corporate, should be credited in the
Acknowledgments section, as described below. In addition, if a
manuscript concerns a commercial product, the manufacturer’s
namemust be indicated in theMaterials andMethods section or
elsewhere in the text, as appropriate, in an obvious manner.
Copyright
To maintain and protect the Society’s ownership and rights
and to continue to afford scientists the opportunity to publish
in high-quality journals, ASM requires the corresponding au-
thor to sign a copyright transfer agreement on behalf of all the
authors. Unless this agreement is executed (without changes
and/or addenda), ASM will not publish the article.
In the copyright transfer agreement signed by an author,
ASM grants to that author (and coauthors) the right to repub-
lish discrete portions of his/her (their) article in any other pub-
lication (print, CD-ROM, and other electronic forms) of
which he/she is (they are) the author(s) or editor(s), on the
condition that appropriate credit is given to the original ASM
publication. This republication right also extends to posting on
a host computer to which there is access via the Internet. Ex-
cept as indicated below, significant portions of the article may
not be reprinted/posted without ASM’s prior written permis-
sion, however, as this would constitute duplicate publication.
Authors may post their own published articles on their per-
sonal or university-hosted (but not corporate, government, or
similar) websites without ASM’s prior written permission pro-
vided that appropriate credit is given (i.e., the copyright lines
shown at the bottom of the first page).
Works authored solely by U.S. government employees are
not subject to copyright protection, so there is no copyright to
be transferred. However, the other provisions of the copyright
transfer agreement, such as author representations of original-
ity and authority to enter into the agreement, apply to U.S.
government employee-authors as well as to other authors.
When funds from theWellcome Trust or Research Councils
UK are used to pay an article open access fee, the article will be
published under the Creative Commons Attribution license
(CC-BY) in accordance with the funding organization’s open
access policies. Authors will be required to notify ASM and
complete the Author Warranty and Provisional License to
Publish at the time of submission.
Copyright for supplemental material (see “Supplemental
Material”) remains with the author, but a license permitting
the posting by ASM is included in the article copyright transfer
agreement. If the author of the article is not also the copyright
owner of the supplemental material, the corresponding author
must send to ASM signed permission from the owner that
allows posting of thematerial, as a supplement to the article, by
ASM. The corresponding author is also responsible for incor-
porating into the supplemental material any copyright notices
required by the owner.
Funding Agency Repositories
The National Institutes of Health (NIH) requests that its
grantee and intramural authors provide copies of their ac-
cepted manuscripts to PubMed Central (PMC) for posting in
the PMCPublic Access Repository. However, JCM authors are
automatically in compliance with this policy and need take no
action themselves. For the past several years, ASM has depos-
ited in PubMedCentral all publications from all ASM journals.
Further, ASM policy is that all primary research articles are
made available to everyone, free, 6 months after publication
through PubMed Central, HighWire, and international
PubMed Central-like repositories. By having initiated these
policies, ASM is in full compliance with NIH policy. For more
information, see http://publicaccess.nih.gov/. ASM also allows
JCM authors whose work was supported by funding agencies
that have public access requirements like those of the NIH
(e.g., the Wellcome Trust) to post their accepted manuscripts
in publicly accessible electronic repositories maintained by
those funding agencies. If a funding agency does not itself
maintain such a site, then ASM allows the author to fulfill that
requirement by depositing the manuscript (not the typeset ar-
ticle) in an appropriate institutional or subject-based open re-
pository established by a government or noncommercial en-
tity.
Since ASMmakes the final, typeset articles from its primary-
research journals available free of charge on the ASM Journals
and PMC websites 6 months after final publication, ASM re-
quests that when submitting the accepted manuscript to PMC
or a similar public access site, the author specify that the post-
ing release date for the manuscript be no earlier than 6
months after publication of the typeset article by ASM and
that a link to the published manuscript on the journal web-
site be provided.
Use of Human Subjects or Animals in Research
The use of human subjects or animals for research purposes
is regulated by the federal government and individual institu-
tions. Authors of manuscripts describing research involving
human subjects or animal experimentation must obtain
approval from their Institutional Review Board (IRB) or Insti-
tutional Animal Care andUse Committee (IACUC), as appro-
priate, prior to manuscript submission. Authors of manu-
scripts that describe multisite research must obtain approval
from each institution’s IRB or IACUC, as appropriate. A state-
ment of IRB or IACUC approval must be included in the
Materials and Methods section. Documentation of IRB or
IACUC status must be made available upon request.
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Patient Identiﬁcation
To protect the privacy of individuals mentioned in clinical
studies, in case histories, and as sources of isolates, do not
identify them by their initials, even as part of a strain designa-
tion. Change the initials to numerals or use randomly chosen
letters. Do not give hospital unit numbers; if a designation is
needed, use only the last two digits of the unit. (Note: estab-
lished designations of some viruses and cell lines, although
they consist of initials, are acceptable [e.g., JC virus, BK virus,
and HeLa cells].)
Provision of Requisite Information for Molecular
Applications
Authors of manuscripts which contain quantitative real-time
PCR applications are encouraged to consult the article con-
cerning minimum information for publication of quantitative
real-time PCR experiments (theMIQE guidelines) by Bustin et
al. (Clin. Chem. 55:611–622, 2009) for guidance as to what
information should be considered for inclusion in their sub-
mission.
Newly determined nucleotide and/or amino acid sequence
data must be deposited and GenBank/ENA/DDBJ accession
numbers must be included in the manuscript no later than the
modification stage of the review process. It is expected that the
sequence data will be released to the public no later than the
publication (online posting) date of the accepted manuscript.
The accession numbers should be included in a separate para-
graph at the end of the Materials and Methods section for
full-length papers or at the end of the text for Short-Form
papers. If conclusions in amanuscript are based on the analysis
of sequences and a GenBank/ENA/DDBJ accession number is
not provided at the time of the review, authors should provide
the annotated sequence data as supplemental material not for
publication.
It is expected that when previously published sequence ac-
cession numbers are cited in a manuscript, the original cita-
tions (e.g., journal articles) will be included in the References
section when possible or reasonable.
Authors are also expected to do elementary searches and
comparisons of nucleotide and amino acid sequences against
the sequences in standard databases (e.g., GenBank) immedi-
ately before manuscripts are submitted and again at the proof
stage.
Analyses should specify the database, and the date of each
analysis should be indicated as, e.g., January 2015. If relevant,
the version of the software used should be specified.
See “Presentation of Nucleic Acid Sequences” for nucleic
acid sequence formatting instructions.
The URLs of the databases mentioned above are as follows:
DNA Data Bank of Japan (DDBJ), http://www.ddbj.nig.ac.jp/;
European Nucleotide Archive (ENA), http://www.ebi.ac.uk
/ena/; andGenBank, National Center for Biotechnology Infor-
mation, http://www.ncbi.nlm.nih.gov/nucleotide.
Proper Use of Locus Tags as Systematic Identiﬁers
for Genes
To comply with recommendations from the International Nu-
cleotide Sequence Database (INSD) Collaborators and to
avoid conflicts in gene identification, researchers should im-
plement the following two fundamental guidelines as stan-
dards for utilization of locus tags in genome analysis, annota-
tion, submission, reporting, and publication. (i) Locus tag
prefixes are systematic gene identifiers for all of the replicons of
a genome and as such should be associated with a single ge-
nome project submission. (ii) New genome projects must be
registered with the INSD, and new locus tag prefixes must be
assigned in cooperation with the INSD to ensure that they
conform to the agreed-upon criteria.
Structural Determinations
Coordinates for new structures of macromolecules must be
deposited in the Protein Data Bank and assigned identification
codes must be included in the manuscript no later than the
modification stage of the review process. It is expected that the
coordinates will be released to the public no later than the
publication (online posting) date of the accepted manuscript.
Authors are encouraged to send coordinates with their original
submission, however, so that reviewers can examine them
alongwith themanuscript. The accession number(s) should be
listed in a separate paragraph at the end of the Materials and
Methods section for full-length papers or at the end of the text
for Short-Form papers.
The URLs for coordinate deposition are http://rcsb-deposit
.rutgers.edu/ and http://pdbdep.protein.osaka-u.ac.jp/en/.
Microarray, Next-Generation Sequencing, or Other
High-Throughput Functional Genomics Data
The entire set of supporting microarray, next-generation se-
quencing, or other high-throughput functional genomics data
must be deposited in the appropriate public database (e.g.,
GEO, ArrayExpress, or CIBEX) and the assigned accession
number(s) must be included in the manuscript no later than
the modification stage of the review process. It is expected that
the data will be released to the public no later than the publi-
cation (online posting) date of the accepted manuscript. Au-
thors are encouraged to send the relevant data with their orig-
inal submission, however, so that reviewers can examine them
alongwith themanuscript. The accession number(s) should be
listed in a separate paragraph at the end of the Materials and
Methods section for full-length papers or at the end of the text
for Short-Form papers.
The URLs of the databases mentioned above are as follows:
Gene ExpressionOmnibus (GEO), http://www.ncbi.nlm.nih.gov
/geo/; ArrayExpress, http://www.ebi.ac.uk/arrayexpress/; and Cen-
ter for Information Biology Gene Expression Database
(CIBEX), http://cibex.nig.ac.jp/data/index.html.
Culture Deposition
JCM expects authors to deposit important strains in publicly
accessible culture collections and to refer to the collections and
strain numbers in the text. Since the authenticity of subcul-
tures of culture collection specimens that are distributed by
individuals cannot be ensured, authors should indicate labo-
ratory strain designations and donor sources as well as original
culture collection identification numbers.
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MycoBank
New scientific names of fungi along with key nomenclatural
and descriptive material must be deposited in MycoBank
(http://www.mycobank.org) and the assigned accession num-
ber(s) must be included in the manuscript no later than the
modification stage of the review process. It is expected that the
data will be released to the public no later than the publication
(online posting) date of the accepted manuscript. Authors are
encouraged to send the relevant data with their original sub-
mission, however, so that reviewers can examine them along
with themanuscript. The accession number(s) should be listed
in a separate paragraph at the end of the Materials and Meth-
ods section for full-length papers or at the end of the text for
Short-Form papers.
Supplemental Material
Supplemental material will be peer reviewed along with the
manuscript and must be uploaded to the eJournalPress (eJP)
peer review system at initial manuscript submission. The deci-
sion to publish the material online with the accepted article is
made by the editor. It is possible that a manuscript will be
accepted but that the supplemental material will not be.
The number of supplemental material files is limited to 10.
Supplemental files should be submitted in the following stan-
dard formats.
• Text, figures, tables, and legends should be included
in a single PDF file. All figures and tables should be
numbered independently and cited at the relevant
point in the manuscript text, e.g. “Fig. S1,” “Fig. S2,”
“Table S3,” etc. Do not duplicate data by presenting
them in both the text of the manuscript and a supple-
mental figure. Each legend should appear below its cor-
responding figure or table. The maximum file size is 8
MB. Please review this sample file for guidance.
• Data set (Excel [.xls]) files should include a brief de-
scription of how the data are used in the paper. The
maximum file size is 20 MB. Please review this sample
file for guidance.
• Movies (Audio Video Interleave [.avi], QuickTime
[.mov], or MPEG files) should be submitted at the de-
sired reproduction size and length and should be ac-
companied by a legend. The maximum file size is 20
MB.
Unlike the manuscript, supplemental material will not
be edited by the ASM Journals staff and proofs will not be
made available. References related to supplementalmaterial
only should not be listed in the References section of an
article; instead, include them with the supplemental mate-
rial. Supplemental material will always remain associated
with its article and is not subject to any modifications after
publication.
Material that has been published previously (print or on-
line) is not acceptable for posting as supplemental material.
Instead, the appropriate reference(s) to the original publica-
tion should be made in the manuscript.
Copyright for the supplemental material remains with the
author, but a license permitting posting by ASMmust be signed
by the corresponding author. If you are not the copyright owner,
youmust provide toASMsigned permission from the owner that
allows posting of the material, as a supplement to your article,
by ASM. You are responsible for including in the supplemental
material any copyright notices required by the owner.
See also “Publication Fees.”
Warranties and Exclusions
Articles published in this journal represent the opinions of the
authors and do not necessarily represent the opinions of ASM.
ASM does not warrant the fitness or suitability, for any purpose,
of any methodology, kit, product, or device described or iden-
tified in an article. The use of trade names is for identification
purposes only and does not constitute endorsement by ASM.
SUBMISSION, REVIEW, AND PUBLICATION PROCESSES
Submission Process
All submissions to JCM must be made electronically via the
eJournalPress (eJP) online submission and peer review system
at the following URL: http://jcm.msubmit.net/cgi-bin/main
.plex. (E-mailed submissions will not be accepted.) First-time
users must create an Author account, which may be used for
submitting to all ASM journals. Instructions for creating an
Author account are available at the aboveURL via the “help for
authors” link, and step-by-step instructions for submitting a
manuscript via eJP are also available through the same link on
the log-in screen or on the account holder’s Home page. Infor-
mation on file types acceptable for electronic submission can
be found under the Files heading in the help for authors screen.
Review Process
All manuscripts are considered to be confidential and are re-
viewed by the editors, members of the editorial board, or qual-
ified ad hoc reviewers.
To expedite the review process, authorsmust recommend at
least three editorial board members who have expertise in the
field, who are not members of their institution(s), who have
not recently been associated with their laboratory(ies), and
who could not otherwise be considered to pose a conflict of
interest regarding the submitted manuscript.
To facilitate the review, copies of in-press and submitted
manuscripts that are important for judgment of the present
manuscript shouldbe includedas supplementalmaterial not
for publication.
When a manuscript is submitted to the journal, it is given a
control number (e.g., JCM00123-15) and assigned to one of
the editors. (Always refer to this control number in commu-
nications with the editor and the Journals Department.) It is
the responsibility of the corresponding author to inform the
coauthors of themanuscript’s status throughout the submission,
review, and publication processes. The reviewers operate under
strict guidelines set forth in “Guidelines for Reviewers” (http:
//www.journals.asm.org/site/misc/reviewguide.xhtml) and are
expected to complete their reviews expeditiously.
The corresponding author is notified, generally within 4 to 6
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weeks after submission, of the editor’s decision to accept, re-
ject, or require modification. When modification is requested,
the corresponding author must either submit the modified
version within 2months or withdraw themanuscript. A point-
by-point response to the reviews must be uploaded as a sepa-
rate file (identified as such), and a compare copy of the man-
uscript (without figures) should be included as a Marked Up
Manuscript if the editor requested one.
Manuscripts that have been rejected, or withdrawn after be-
ing returned formodification, may be resubmitted to the same
ASM journal if the major criticisms have been addressed. A
manuscript rejected by one ASM journal on scientific grounds
or on the basis of its general suitability for publication is con-
sidered rejected by all other ASM journals; however, a manu-
script rejected solely on the basis of scope may be “resubmit-
ted” to a more appropriate ASM journal.
For all resubmissions (to the same or a different journal,
irrespective of the extent of the revisions and irrespective of the
amount of time between rejection and resubmission), the
cover letter must state that the manuscript is a resubmission,
and the formermanuscript control numbermust be provided.
A point-by-point response to the review(s) must be uploaded
as a separate file (identified as such), and a compare copy of the
revised manuscript showing all changes must be included as a
Marked UpManuscript. Manuscripts resubmitted to the same
journal are normally handled by the original editor.
Rejected manuscripts may be resubmitted only once unless
permission has been obtained from the original editor or from
the editor in chief.
Notiﬁcation of Acceptance
When an editor has decided that amanuscript is acceptable for
publication on the basis of scientific merit, the author and the
Journals Department are notified. A PDF version of the ac-
cepted manuscript is posted online as soon as possible (see
“JCM Accepts”).
The text files undergo an automated preediting, cleanup,
and tagging process specific to the particular article type, and
the illustrations are examined. If all files have been prepared
according to the criteria set forth in these Instructions and
those in the eJP online manuscript submission system, the ac-
ceptance procedure will be completed successfully. If there are
problems that would cause extensive corrections to bemade at
the copyediting stage or if the files are not acceptable for pro-
duction, ASM Journals staff will contact the corresponding
author. Once all thematerial intended for publication has been
determined to be adequate, themanuscript is scheduled for the
next available issue. The editorial staff of the ASM Journals
Department completes the editing of themanuscript to bring it
into conformity with prescribed standards.
JCM Accepts
For its primary-research journals, ASM posts online PDF ver-
sions of manuscripts that have been peer reviewed and ac-
cepted but not yet copyedited. This feature is called “[journal
acronym] Accepts” (e.g., JCM Accepts) and is accessible from
the Journals website. The manuscripts are published online as
soon as possible after acceptance, on a weekly basis, before the
copyedited, typeset articles are published. They are posted “as
is” (i.e., as submitted by the authors at the modification stage)
and do not reflect ASM editorial changes. No corrections/
changes to the PDF manuscripts are accepted. Accordingly,
there likely will be differences between the JCM Accepts man-
uscripts and the final, typeset articles. Themanuscripts remain
listed on the JCM Accepts page until the final, typeset articles
are posted. At that point, the manuscripts are removed from
the JCM Accepts page. The manuscripts are under subscrip-
tion access control until 6 months after the typeset articles are
posted, when free access is provided to everyone (subject to the
applicable ASM license terms and conditions). Supplemental
material intended, and accepted, for publication is not posted
until publication of the final, typeset article.
The ASM embargo policy allows a press release to be issued
as soon as the accepted manuscript is posted on the JCM Ac-
cepts page. To be notified as soon as yourmanuscript is posted,
please sign up for e-Alerts at http://jcm.asm.org/cgi/alerts.
Instructions on how to cite such manuscripts may be found
in “References.”
Page Proofs
Page proofs, together with a query sheet and instructions for
handling proofs, will be made available to the corresponding
author electronically. Queries must be answered on the query
page, and any changes related to the queries, as well as any
additional changes, must be indicated on the proofs. Note that
the copy editor does not query at every instancewhere a change
has been made. Queries are written only to request necessary
information or clarification of an unclear passage or to draw
attention to edits that may have altered the sense. It is the
author’s responsibility to read the entire text, tables, and figure
legends, not just items queried. Corrected proofs must be re-
turned within two business days after notification of availabil-
ity.
The proof stage is not the time to make extensive correc-
tions, additions, or deletions. Figures as they appear in the
proofs are for validation of content and placement, not quality
of reproduction or color accuracy. Print output of figures in
the PDF page proofs will be of lower quality than the same
figures viewed on a monitor. Please avoid making changes to
figures based on quality of color or reproduction in proof.
Important new information that has become available be-
tween acceptance of the manuscript and receipt of the proofs
may be inserted as an addendum in proof with the permission
of the editor. If references to unpublished data or personal
communications are added, it is expected that written assur-
ance granting permission for the citation will be included.
Limit changes to correction of spelling errors, incorrect data,
and grammatical errors and updated information for refer-
ences to articles that have been submitted or are in press. If
URLs have been provided in the article, recheck the sites to
ensure that the addresses are still accurate and thematerial that
you expect the reader to find is indeed there.
Questions about late proofs and problems with the proofs
should be directed to the ASM Journals Department (e-mail,
cbrown@asmusa.org; telephone, 202-942-9384).
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PDF Files
A corresponding author who has included an e-mail address in
his/her “corresponding author” footnote will have limited ac-
cess (10 downloads, total) to the PDF file of his/her published
article. An e-mail alert will automatically be sent to him/her on
the day the issue is posted. It will provide a URL, which will be
required to obtain access, and instructions. An article may be
viewed, printed, or stored, provided that it is for the author’s
own use.
Should coauthors or colleagues be interested in viewing the
paper for their ownuse, the corresponding authormay provide
themwith the URL; a copy of the article may not be forwarded
electronically. However, theymust bemade aware of the terms
and conditions of the ASM copyright. (For details, go to http:
//www.journals.asm.org/site/misc/terms.xhtml.) Note that
each such download will count toward the corresponding au-
thor’s total of 10. After 10 downloads, access will be denied and
can be obtained only through a subscription to the journal
(either individual or institutional) or after the standard access
control has been lifted (i.e., 6 months after publication).
Publication Fees
Page charges. Authors whose research was supported by
grants, special funds (including departmental and institu-
tional), or contracts (including governmental) or whose re-
search was done as part of their official duties (government or
corporate, etc.) are required to pay page charges (based on the
number of typeset pages, including illustrations, in the article).
Corresponding authors of articles accepted for publicationwill
receive an e-mail notifying themhow topay page and any other
applicable publication charges (see below).
For a corresponding author who is an active member of
ASM at the Contributing or Premium level, page charges are
$67 per page for the first eight pages and $125 per page for each
page in excess of eight (subject to change without notice).
For a nonmember or Supporting member corresponding
author, page charges are $135 per page for the first eight pages
and $250 for each page in excess of eight (subject to change
without notice). Nonmember corresponding authors or Sup-
porting members may join ASM and renew or upgrade mem-
bership online to obtain discounts on publication fees.
If the research was not supported by any of the means
described above, a request to waive the charges may be sent
to the Journals Department, ASM (fax, 202-942-9355; e-mail,
cbrown@asmusa.org [after acceptance of the manuscript]).
The request must include the manuscript control number as-
signed by ASM and indicate how the work was supported.
Waivers apply only to page charges; responsibility for color
charges and other publication fees remains with the author.
Minireviews, Commentaries, PhotoQuizzes, andComment
Letters to the Editor are not subject to page charges. New-Data
Letters to the Editor are subject to page charges.
Color charges. The cost of publishing in color must be
borne by the author.
For a corresponding author who is an active member of
ASM at the Contributing or Premium level, color charges are
$170 per color figure (subject to change without notice).
For a nonmember or Supporting member corresponding
author, color charges are $375 per color figure (subject to
change without notice). Nonmember corresponding authors
or Supporting members may join ASM and renew or upgrade
membership online to obtain discounts on publication fees.
Minireviews, Commentaries, PhotoQuizzes, andComment
Letters to the Editor are not subject to color charges. New-Data
Letters to the Editor are subject to color charges.
Author reprints and eprints. Reprints (in multiples of
100) and eprints (downloadable PDFs) may be purchased by
all coauthors. In addition to the 10 free published PDF files
mentioned above, the corresponding authors of Minireviews
may receive 100 free eprints of their contribution and the cor-
responding authors of Commentaries may receive 50 free
eprints. Instructions for ordering gratis or additional reprints
and eprints can be found in the billing notification e-mail sent
to all corresponding authors. To order reprints postpublica-
tion, please follow the instructions on the Author Reprint Or-
der Form. Please contact cjsreprints@cadmus.com with any
questions.
Supplemental material fee. Authors are charged a flat fee
for posting supplemental material as an adjunct to their pub-
lished article. (Exception: no fee is charged for supplemental
material associated with Minireviews or Commentaries.)
For a corresponding author who is an active member of
ASMat theContributing or Premium level, the supplemental
material fee is $190. For a nonmember or Supporting mem-
ber corresponding author, the supplemental material fee is
$285. Nonmember corresponding authors or Supporting
members may join ASM and renew or upgrade membership
online to obtain discounts on publication fees.
Optional open access fee. Author-paid optional open ac-
cess (OOA) is now available for all article types. For a corre-
sponding author who is an active member of ASM at the
Contributing or Premium level, the OOA fee is $2,000. For a
nonmember or Supporting member corresponding author,
the OOA fee is $3,000. Nonmember corresponding authors or
Supporting members may join ASM and renew or upgrade
membership online to obtain discounts on publication fees.
These fees are in addition to any page charges, color charges, or
supplemental material charges and permit immediate public
access to both the preliminary “Accepts” version and the copy-
edited, typeset version published in the online journal. This
option includes immediate open access provided through
NIH’s PubMed Central repository; all primary research pub-
lished in ASM journals is freely available through PubMed
Central 6 months after publication.
When funds from theWellcome Trust or Research Councils
UK are used to pay an article open access fee, the article will be
published under the Creative Commons Attribution license
(CC-BY) in accordance with the funding organization’s open
access policies. Authors will be required to notify ASM and
complete the Author Warranty and Provisional License to
Publish at the time of submission.
Instructions to Authors
8 January 2015, Instructions to Authors Journal of Clinical Microbiology jcm.asm.org
ORGANIZATION AND FORMAT
Editorial Style
The editorial style of ASM journals conforms to the ASM Style
Manual for Journals (American Society for Microbiology,
2015, in-house document) and How To Write and Publish a
Scientific Paper, 7th ed. (Greenwood, Santa Barbara, CA,
2011), as interpreted andmodified by the editors and the ASM
Journals Department.
The editors and the Journals Department reserve the privi-
lege of editing manuscripts to conform with the stylistic con-
ventions set forth in the aforesaid publications and in these
Instructions.
On receipt at ASM, an accepted manuscript undergoes an
automated preediting, cleanup, and tagging process specific to
the particular article type. To optimize this process, manu-
scripts must be supplied in the correct format and with the
appropriate sections and headings.
Type every portion of the manuscript double-spaced (a
minimum of 6 mm between lines), including figure legends,
table footnotes, and References, and number all pages in se-
quence, including the abstract, figure legends, and tables. Place
the last two items after the References section. Manuscript
pages must have continuous line numbers and page numbers.
Manuscripts without line and page numbers will be returned
to authors for provision of this information prior to process-
ing. The font size should be no smaller than 12 points. It is
recommended that the following sets of characters be easily
distinguishable in the manuscript: the numeral zero (0) and
the letter “oh” (O); the numeral one (1), the letter “el” (l), and
the letter “eye” (I); and amultiplication sign () and the letter
“ex” (x). Do not create symbols as graphics or use special fonts
that are external to your word processing program; use the
“insert symbol” function. Set the page size to 8.5 by 11 inches
(ca. 21.6 by 28 cm). Italicize any words that should appear in
italics, and indicate paragraph lead-ins in boldface type.
Manuscripts may be editorially rejected, without review,
on thebasis of poorEnglish or lackof conformity to the stan-
dards set forth in these Instructions.
Authors who are unsure of proper English usage should
have their manuscripts checked by someone proficient in the
English language or engage a professional language editing ser-
vice for help.
Manuscript Submission Checklist
• Double-space all text, including references and figure
legends.
• Number pages.
• Number lines continuously.
• Present statistical treatment of data where appropriate.
• Format references in ASM style.
• Provide accession numbers for all newly published se-
quences in a dedicated paragraph, and if a sequence or
sequence alignment important for evaluation of the
manuscript is not yet available, provide the informa-
tion as supplemental material not for publication or
make the material available on a website for access by
the editor and reviewers.
• Confirm that genetic and chemical nomenclature con-
forms to instructions.
• Include as supplemental material not for publication
in-press and submittedmanuscripts that are important
for judgment of the present manuscript.
Full-Length Papers
Full-length papers include the elements described in this sec-
tion.
Title, running title, byline, affiliation line, and corre-
sponding author. Eachmanuscript should present the results
of an independent, cohesive study; thus, numbered series titles
are not permitted. Exercise care in composing a title. Avoid the
main title/subtitle arrangement, complete sentences, and un-
necessary articles. On the title page include the title, the run-
ning title (not to exceed 54 characters and spaces), the name of
each author, all authors’ affiliations at the time the work was
performed, the name(s) and e-mail address(es) of the corre-
sponding author(s), and a footnote indicating the present ad-
dress(es) of any author(s) no longer at the institution where
the work was performed. Place a number sign (#) in the byline
after the name of the author to whom inquiries regarding the
paper should be directed (see “Correspondent footnote,” be-
low). Please review this sample title page for guidance.
Study group in byline. A study group, surveillance team,
working group, consortium, or the like (e.g., the Active Bacte-
rial Core Surveillance Team)may be listed as a coauthor in the
byline if its contributing members satisfy the requirements for
authorship and accountability as described in these Instruc-
tions. The names (and institutional affiliations if desired) of
the contributing members may be given as a separate para-
graph in Acknowledgments.
If the contributingmembers of the group associatedwith the
work do not fulfill the criteria of substantial contribution to
and responsibility for the paper, the groupmay not be listed in
the author byline. Instead, it and the names of its contributing
members may be listed in the Acknowledgments section.
Correspondent footnote. The e-mail address for the cor-
responding author should be included on the title page of the
manuscript. This informationwill be published in the article as
a footnote to facilitate communication and will be used to no-
tify the corresponding author of the availability of proofs and,
later, of the PDF file of the published article. Nomore than two
authors may be designated corresponding authors.
Abstract. Limit the abstract to 250words or fewer and con-
cisely summarize the basic content of the paper without pre-
senting extensive experimental details. Avoid abbreviations
and references, and do not include diagrams.When it is essen-
tial to include a reference, use the format shown under “Refer-
ences” below (see the “Citations in abstracts” section). Con-
clude the abstract with a summary statement. Because the
abstract will be published separately by abstracting services, it
must be complete and understandable without reference to the
text.
Introduction. The introduction should supply sufficient
background information to allow the reader to understand and
evaluate the results of the present study without referring to
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previous publications on the topic. The introduction should
also provide the hypothesis that was addressed or the rationale
for the present study. Choose references carefully to provide
the most salient background rather than an exhaustive review
of the topic.
Materials and Methods. The Materials and Methods sec-
tion must include sufficient technical information to allow the
experiments to be repeated. The sources of all media (i.e.,
name and location of manufacturer) or components of a new
formulation must be provided. When centrifugation condi-
tions are critical, give enough information to enable another
investigator to repeat the procedure: make of centrifuge,
model of rotor, temperature, time at maximum speed, and
centrifugal force ( g rather than revolutions perminute). For
commonly used materials and methods (e.g., media and pro-
tein concentration determinations), a simple reference or spe-
cifically recommended product or procedure is sufficient. If
several alternative methods are commonly used, it is helpful to
identify the method briefly as well as to cite the reference. For
example, it is preferable to state “cells were broken by ultra-
sonic treatment as previously described (9)” rather than to
state “cells were broken as previously described (9).” This al-
lows the reader to assess the method without constant refer-
ence to previous publications. Describe new methods com-
pletely, and give sources of unusual chemicals, reagents,
equipment, or microbial strains. When large numbers of mi-
crobial strains or mutants are used in a study, include tables
identifying the immediate sources (i.e., sources from whom
the strains were obtained) and properties of the strains, mu-
tants, bacteriophages, and plasmids, etc.
A method or strain, etc., used in only one of several experi-
ments reported in the paper may be described in the Results
section or very briefly (one or two sentences) in a table foot-
note or figure legend. It is expected that the sources from
whom the strains were obtained will be identified.
Results. In the Results section, include the rationale or de-
sign of the experiments as well as the results; reserve extensive
interpretation of the results for the Discussion section. Present
the results as concisely as possible in one of the following: text,
table(s), or figure(s). Avoid extensive use of graphs to present
data which might be more concisely presented in the text or
tables. For example, except in unusual cases, double-reciprocal
plots used to determine apparentKm values should not be pre-
sented as graphs; instead, the values should be stated in the
text. Similarly, graphs illustrating other methods commonly
used to derive kinetic or physical constants (e.g., reduced-vis-
cosity plots and plots used to determine sedimentation veloc-
ity) need not be shown except in unusual circumstances. All
tabular datamust be accompanied by either standard deviation
values or standard errors of the means. The number of repli-
cate determinations (or animals) used for making such calcu-
lations must also be included. All statements concerning the
significance of the differences observed should be accompa-
nied by probability values given in parentheses. The statistical
procedure used should be stated in Materials and Methods.
Limit illustrations (particularly photomicrographs and elec-
tron micrographs) to those that are absolutely necessary to
show the experimental findings. Number figures and tables in
the order in which they are cited in the text, and be sure to cite
all figures and tables.
Discussion. The Discussion section should provide an in-
terpretation of the results in relation to previously published
work and to the experimental system at hand. It must not con-
tain extensive repetition of the Results section or reiteration of
the introduction. In short papers, the Results and Discussion
sections may be combined.
Acknowledgments. The source of any financial support
received for the work being publishedmust be indicated in the
Acknowledgments section. (It will be assumed that the absence
of such an acknowledgment is a statement by the authors that
no support was received.) The usual format is as follows: “This
work was supported by Public Health Service grant CA-01234
from the National Cancer Institute.”
Recognition of personal assistance should be given as a sep-
arate paragraph, as should any conflict of interest statements
and statements disclaiming endorsement or approval of the
views reflected in the paper or of a product mentioned therein.
Appendixes. Appendixes that contain additional material
to aid the reader are permitted. Titles, authors, and reference
sections that are distinct from those of the primary article are
not allowed. If it is not feasible to list the author(s) of the
appendix in the byline or the Acknowledgments section of the
primary article, rewrite the appendix so that it can be consid-
ered for publication as an independent article, either full-
length paper or Short-Form style. Equations, tables, and fig-
ures should be labeled with the letter “A” preceding the
numeral to distinguish them from those cited in themain body
of the text.
References. In the reference list, references are numbered
in the order in which they are cited in the article (citation-
sequence reference system); ASM no longer uses the citation-
name system with an alphabetized reference list. In the text,
references are cited parenthetically by number in sequential
order. Data that are not published or not peer reviewed are
simply cited parenthetically in the text (see section ii below).
(i) References listed in the References section. The follow-
ing types of references must be listed in the References section:
• Journal articles (both print and online)
• Books (both print and online)
• Book chapters (book title is required)
• Patents
• Theses and dissertations
• Published conference proceedings
• Meeting abstracts (from published abstract books or
journal supplements)
• Letters (to the editor)
• Company publications
• In-press journal articles, books, and book chapters
(publication title is required)
Provide the names of all the authors and/or editors for each
reference; names should not be abbreviated with “et al.”
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Since title and byline information that is downloaded from
PubMed does not always show accents, italics, or special char-
acters, authors should refer to the PDF files or hard-copy ver-
sions of the articles and incorporate the necessary corrections
in the submitted manuscript. Abbreviate journal names ac-
cording to the PubMed Journals Database (National Library of
Medicine, National Institutes of Health; available at http:
//www.ncbi.nlm.nih.gov/nlmcatalog/journals), the primary
source for ASM style (do not use periods with abbreviated
words). The EndNote output style for ASM Journals’ current
reference style can be found here; click “Open” and then
“Download and Install” to save it to your EndNote Styles folder
(it should replace any earlier output styles for ASM journals
[all ASM journals use the same reference style]).
Follow the styles shown in the examples below for print
references.
1. Caserta E, Haemig HAH, Manias DA, Tomsic J, Grundy
FJ, Henkin TM, Dunny GM. 2012. In vivo and in vitro
analyses of regulation of the pheromone-responsive prgQ
promoter by the PrgX pheromone receptor protein. J Bac-
teriol 194:3386–3394.
2. Falagas ME, Kasiakou SK. 2006. Use of international
units when dosing colistin will help decrease confusion
related to various formulations of the drug around the
world. Antimicrob Agents Chemother 50:2274–2275.
(Letter.) {“Letter” or “Letter to the editor” is allowed but not
required at the end of such an entry.}
3. Cox CS, Brown BR, Smith JC. J Gen Genet, in press.*
{Article title is optional; journal title is mandatory.}
4. daCostaMS, NobreMF, Rainey FA. 2001. Genus I. Ther-
mus Brock and Freeze 1969, 295,AL emend. Nobre, Tru¨per
and da Costa 1996b, 605, p 404–414. In Boone DR, Cas-
tenholz RW, Garrity GM (ed), Bergey’s manual of system-
atic bacteriology, 2nd ed, vol 1. Springer, New York, NY.
5. Stratagene. 2006. Yeast DNA isolation system: instruction
manual. Stratagene, La Jolla, CA. {Use the company name
as the author if none is provided for a company publication.}
6. Forman MS, Valsamakis A. 2011. Specimen collection,
transport, and processing: virology, p 1276–1288. In Ver-
salovic J, Carroll KC, Jorgensen JH, Funke G, Landry ML,
Warnock DW (ed), Manual of clinical microbiology, 10th
ed, vol 2. ASM Press, Washington, DC.
7. Fitzgerald G, Shaw D. InWaters AE (ed), Clinical micro-
biology, in press. EFH Publishing Co, Boston, MA.*
{Chapter title is optional.}
8. Garcı´a CO, Paira S, BurgosR,Molina J,Molina JF, Calvo
C, Vega L, Jara LJ, Garcı´a-Kutzbach A, Cuellar ML,
Espinoza LR. 1996. Detection of SalmonellaDNA in syno-
vial membrane and synovial fluid from Latin American
patients using the polymerase chain reaction. Arthritis
Rheum 39(Suppl 9):S185. {Meeting abstract published in
journal supplement.}
9. Carlson E. 2013. Selective penicillin-binding protein im-
aging probes reveal substructure in bacterial cell division,
p 59. Final Program 113th Gen Meet Am Soc Microbiol.
American Society for Microbiology, Washington, DC.
{Abstract title is optional.}
10. Rotimi VO, Salako NO, Mohaddas EM, Philip LP. 2005.
Abstr 45th Intersci Conf Antimicrob Agents Chemother,
abstr D-1658. {Abstract title is optional.}
11. Green PN, Hood D, Dow CS. 1984. Taxonomic status of
some methylotrophic bacteria, p 251–254. In Crawford
RL, Hanson RS (ed),Microbial growth on C1 compounds.
Proceedings of the 4th International Symposium. Ameri-
can Society for Microbiology, Washington, DC.
12. O’Malley DR. 1998. Ph.D. thesis. University of California,
Los Angeles, CA. {Title is optional.}
13. Odell JC. April 1970. Process for batch culturing. US pat-
ent 484,363,770. {Include the name of the patented item/
process if possible; the patent number is mandatory.}
14. Elder BL, Sharp SE. 2003. Cumitech 39, Competency as-
sessment in the clinical laboratory. Coordinating ed,
Sharp SE. ASM Press, Washington, DC.
*A reference to an in-press ASM publication should state the
control number (e.g., JCM00123-15) if it is a journal article or
the name of the publication if it is a book.
Online-only references must provide essentially the same
information that print references do. For online journal arti-
cles, posting or revision dates may replace the year of publica-
tion; a DOI (preferred) or URL is required for articles with
nontraditional page numbers or electronic article identifiers.
1. Bina XR, Taylor DL, Vikram A, Ante VM, Bina JE. 2013.
Vibrio cholerae ToxR downregulates virulence factor pro-
duction in response to cyclo(Phe-Pro). mBio 4(5):e00366-
13. doi:10.1128/mBio.00366-13.
2. Winnick S, Lucas DO,Hartman AL, Toll D. 2005. How do
you improve compliance? Pediatrics 115:e718–e724. doi:
10.1542/peds.2004-1133.
3. DionneMS, Schneider DS. 2002. Screening the fruitfly im-
mune system. Genome Biol 3:reviews1010-reviews1010.2.
doi:10.1186/gb-2002-3-4-reviews1010.
4. Giege´ R, Springer M. 2012. Aminoacyl-tRNA synthetases
in the bacterial world. EcoSal Plus doi:10.1128/ecosalplus
.4.2.1.
Note: a posting or accession date is required for any online
reference that is periodically updated or changed.
Citations of ASM Accepts manuscripts should look like the
following example.
WangGG, PasillasMP,KampsMP. 15May 2006. Persis-
tent transactivation by Meis1 replaces Hox function in
myeloid leukemogenesis models: evidence for co-occu-
pancy ofMeis1-Pbx andHox-Pbx complexes on promot-
ers of leukemia-associated genes. Mol Cell Biol doi:
10.1128/MCB.00586-06.
Other journals may use different styles for their publish-
ahead-of-print manuscripts, but citation entries must include
the following information: author name(s), posting date, title,
journal title, and volume and page numbers and/or DOI. The
following is an example:
Zhou FX, Merianos HJ, Brunger AT, Engelman DM. 13
February 2001. Polar residues drive association of
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polyleucine transmembrane helices. Proc Natl Acad Sci
U S A doi:10.1073/pnas.041593698.
(ii) References cited in the text. References that should be
cited in the text include
• Unpublished data
• Manuscripts submitted for publication
• Unpublished conference presentations (e.g., a report
or poster that has not appeared in published confer-
ence proceedings)
• Personal communications
• Patent applications and patents pending
• Computer software, databases, and websites
These references should be made parenthetically in the text as
follows:
. . . similar results (R. B. Layton and C. C. Weathers, un-
published data).
. . . system was used (J. L. McInerney, A. F. Holden, and
P. N. Brighton, submitted for publication).
. . . as described previously (M. G. Gordon and F. L. Ratt-
ner, presented at the Fourth Symposium on Food Mi-
crobiology, Overton, IL, 13 to 15 June 1989). {For non-
published abstracts and posters, etc.}
. . . this new process (V. R. Smoll, 20 June 1999, Austra-
lian Patent Office). {For non-U.S. patent applications,
give the date of publication of the application.}
. . . available in the GenBank database (http://www.ncbi
.nlm.nih.gov/Genbank/index.html).
. . . using ABC software (version 2.2; Department of Mi-
crobiology, State University [http://www.state.micro
.edu]).
URLs for companies that produce any of the products men-
tioned in your study or for products being sold may not be
included in the article. However, company URLs that permit
access to scientific data related to the study or to shareware
used in the study are permitted.
(iii) Citations in abstracts. Because the abstract must be
able to stand apart from the article, references cited in it
should be clear without recourse to the References section. Use
an abbreviated form of citation, omitting the article title, as
follows.
(P. S. Satheshkumar, A. S. Weisberg, and B. Moss, J Virol
87:10700–10709, 2013, doi:10.1128/JVI.01258-13)
(J. H. Coggin, Jr., p. 93–114, in D. O. Fleming and D. L.
Hunt, ed., Biological Safety. Principles and Practices, 4th
ed., 2006)
“. . . in a recent report by D. A. Hopwood [mBio 4(5):
e00612-13, 2013, doi:10.1128/mBio00612-13] . . . .”
This style should also be used for Addenda in Proof.
(iv) References related to supplemental material. If refer-
encesmust be cited in the supplemental material, list them in a
separate References section within the supplemental material
and cite them by those numbers; do not simply include cita-
tions of numbers from the reference list of the associated arti-
cle. If the same reference(s) is to be cited in both the article
itself and the supplemental material, then that reference would
be listed in both References sections.
Short-Form Papers
The Short-Form format is intended for the presentation of
brief observations that do not warrant full-length papers.
However, Short-Form papers should contain firm data; obser-
vations alone are not acceptable. Submit Short-Form papers in
the same way as full-length papers. They receive the same re-
view, they are not published more rapidly than full-length pa-
pers, and they are not considered preliminary communica-
tions.
The title, running title (not to exceed 54 characters and
spaces), byline, and correspondent footnote should be pre-
pared as for a full-length paper. Each Short-Form paper must
have an abstract of no more than 50 words. Do not use section
headings in the body of the Short Form; combine methods,
results, and discussion in a single section. Paragraph lead-ins
are permissible. The text should be kept to a minimum and if
possible should not exceed 1,000 words; the number of figures
and tables should also be kept to a minimum. Materials and
methods should be described in the text, not in figure legends
or table footnotes. Present acknowledgments as in full-length
papers. The References section is identical to that of full-length
papers.
Minireviews
Minireviews are expected to be focused discussions of defined
topics relevant to clinical microbiologists. In general, they are
to be submitted only following invitation by the editor in chief
of JCM. Unsolicited Minireviews are discouraged. A topical
outline should be provided to the editor in chief for approval
prior to submission of the completed Minireview manuscript
in the eJP online manuscript submission and peer review sys-
tem.
Minireviews are not expected to be comprehensive reviews
of the literature but rather focused discussions of specific top-
ics. A standard title page should be provided. This is followed
by an abstract of 100 words or less and then the text of the
Minireview, which should not exceed 12 double-spaced man-
uscript pages in length, exclusive of tables, figures, photo-
graphs, and references. Up to three tables, figures, or photo-
graphs, total, may be included. References should be limited to
no more than 30. Minireviews will be reviewed by two JCM
editors, with the aim of expedited processing. In general, it is
hoped that, barring the necessity of major revisions, accepted
Minireviews will appear in print within 3 months of their sub-
mission and online ahead of print 6 to 8 weeks earlier.
Author bio. A short biographical sketch and photograph of
the one author most responsible for the minireview should be
submitted along with the initial version of the manuscript.
These will be published at the end of the article.
• The text limit is 150 words and should include WHO
you are (your name), WHERE you received your edu-
cation,WHAT positions you have held and atWHICH
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institutions, WHERE you are now (your current insti-
tution),WHY you have this interest, andHOWLONG
you have been in this area, as well as a brief review of
your scholarly interests and record of publication. In
addition, please list pertinent significant awards you
have received.
• The photo should be a recent black-and-white head
shot of passport size. It will be reduced to approxi-
mately 1.125 inches wide by 1.375 inches high. The
photo must meet the production criteria for regu-
lar figures and should be checked for production
quality by using Rapid Inspector, provided at the fol-
lowingURL: http://rapidinspector.cadmus.com/Rapid
Inspector/zmw/index.jsp.
• To submit, upload the text and photo with your man-
uscript in the submission and review system. Include
the biographical text immediately after the References
section of your manuscript, in the same file. It should
be labeled with the heading “Biosketch.” Upload the
head shot photograph in the submission system as a
“MinireviewBioPhoto”; include the author’snameor
enough of it for identification in the photo’s file
name.
Contact the scientific editor if you have questions about what
to write. Contact the production editor if you have questions
about submitting your files.
Commentaries
Commentaries are invited communications concerning topics
relevant to the readership of JCMand are intended to engender
discussion. Reviews of the literature, methods and other
how-to papers, and responses targeted at a specific published
paper are not appropriate. Commentaries are subject to re-
view.
The length may not exceed four printed pages, and the for-
mat is like that of a Minireview (see above) except that the
abstract is limited to 75 words.
Point-Counterpoint
Point-Counterpoint is a feature of JCM in which two experts
present opposing views on a contemporary issue in the labora-
tory diagnosis of infectious diseases. This feature will be the
lead article in the issue of JCM in which it appears. Participa-
tion as an author of a Point-Counterpoint feature is by invita-
tion only.
A JCMeditor will write a brief introductory piece of approx-
imately 200 words outlining why a specific issue is important
and then present the issue in the form of a question. The two
experts will then eachwrite a commentary, nomore than 1,000
words in length, in which they present evidence in support of
either the pro or con view. One table or one figure may be
included. Since these discussions will be evidence based, au-
thors may also cite up to 10 references. Unpublished or in-
press data which reflect the current practice in their laboratory
may be used but should not be the sole basis for their position.
Authors should send commentaries directly back to the JCM
editor within 30 days of receipt of the introductory statement.
Following receipt of both the pro and con commentaries, the
editor will review the submissions and may return them to the
author(s) with comments and/or suggested revisions. If revi-
sions are required, the author(s) will have 14 days to craft a
revised commentary, which will be sent directly back to the
editor.Upon receipt of final commentaries, the JCMeditorwill
write a brief summary consisting of no more than six one-
sentence bullet points, outlining where the experts agree (no
more than three points) and disagree (no more than three
points). The JCM editor will then upload the introduction,
both commentaries, and the summary in eJP.
Case Reports
A Case Report must include an abstract of no more than 50
words. The text starts with presentation of the case under the
section heading “Case Report”; there is no introductory text
before the Case Report heading. After the case is presented, the
rest of the text follows in a separate section after a ruled line to
separate the sections. No separate head is used for this short
discussion section, but paragraph lead-ins are permitted. The
total number of tables and figures (combined)must not exceed
3. For an example of a correctly formatted Case Report, see
J Clin Microbiol 39:1678–1679, 2001.
Photo Quiz
A Photo Quiz submission should present the findings of some
relevant, interesting, and new observation pertinent to the
practice of clinical microbiology in which a photograph is par-
ticularly useful in conveying important information and
where the observation can serve as the basis for both a question
and an answer. The photographmay be of amicrograph, some
other laboratory material, a clinical lesion, or the results of an
imaging study.
A Photo Quiz consists of two parts: (i) a case presentation
featuring a photograph depicting some unusual and/or infor-
mative finding in clinical microbiology and (ii) an answer to
the quiz. The case presentation and the answer must be sub-
mitted as two separate articles. Note that authors and affilia-
tions are listed below the title.
Photo Quiz case presentation. The text in the Photo Quiz
case presentation should be limited to 200 to 300 words. The
header for the case presentation should read “Photo Quiz.”
Please include a photograph about 39 picas (6.5 inches)wide
and 28 picas (4.625 inches) high. Since photos appearing with
published Photo Quizzes appear on the cover of the journal, a
high-resolutionTIFF or EPS file is preferred. A short legend for
the photomust be provided, and the photomust be cited in the
case presentation. Refer to a recently published Photo Quiz for
correct formatting.
Answer to Photo Quiz. The text of the answer to the Photo
Quiz should also be limited to 200 to 300 words. The header to
the answer should read “Answer to Photo Quiz.” Four to six
references may be cited at the end of the Photo Quiz answer.
Submission. The Photo Quiz case presentation should be
submitted in the “Photo Quiz” manuscript category. The
Photo Quiz answer should be submitted in the “Photo Quiz
Answer” manuscript category.
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Letters to the Editor
Two types of Letters to the Editor may be submitted. The first
type (Comment Letter) is intended for comments on final,
typeset articles published in the journal (not on acceptedman-
uscripts posted online) and must cite published references to
support the writer’s argument. The second type (New-Data
Letter)may report new, concise findings that are not appropri-
ate for publication as full-length papers or Short-Form papers.
Letters may be no more than 500 words long and must be
typed double spaced. Refer to a recently published Letter for
correct formatting. Note that authors and affiliations are listed
below the title.
All Letters to the Editor must be submitted electronically,
and the type of Letter (New Data or Comment) must be se-
lected from the drop-down list in the submission form. For
Letters commenting on published articles, the cover letter
should state the volume and issue in which the article was
published, the title of the article, and the last name of the first
author. In the Abstract section of the submission form, put
“Not Applicable.” Letters to the Editor do not have abstracts.
Both types of Lettermust have a title, whichmust appear on the
manuscript and on the submission form. Figures and tables
should be kept to a minimum.
If the Letter is related to a published article, it will be sent to
the editor who handled the article in question. If the editor
believes that publication is warranted, he/she will solicit a reply
from the corresponding author of the article and give approval
for publication.
New-Data Letters will be assigned to an editor according to
subject matter and will be reviewed by that editor and/or a
reviewer.
Please note that some indexing/abstracting services do not
include Letters to the Editor in their databases.
Fast-Track Communications
The Fast-Track route is intended for accelerated review of
short communications that are of significant interest to clinical
microbiologists. Manuscripts are limited to 750 words, one
figure, one table, and 10 or fewer references. The format should
be the same as that of a New-Data Letter (see “Letters to the
Editor,” above). Fast-Track articles should be submitted via
the eJP online manuscript submission and peer review system.
A Fast-Track submission is subject to approval as such by
the editor in chief. If approved for the Fast-Track route, the
manuscript will be assigned to an appropriate JCM editor and
reviewed, according to the same standards applied for tradi-
tional manuscripts, within 1 week. If accepted, the manuscript
will be scheduled for the next available issue and edited. An
acceptance letter and copyright agreementwill bemailed to the
corresponding author. Proofs will be made available electron-
ically as for regular articles.
A Fast-Track submission that is not approved for the Fast-
Track route will be handled as a New-Data Letter according to
normal procedures.
Errata
The Erratum section provides ameans of correcting errors that
occurred during the writing, typing, editing, or publication
(e.g., a misspelling, a dropped word or line, or mislabeling in a
figure) of a published article. Submit Errata via the eJP online
manuscript submission and peer review system (see “Submis-
sion, Review, and Publication Processes”). In the Abstract sec-
tion of the submission form (a required field), put “Not Appli-
cable.” Upload the text of your Erratum as a Microsoft Word
file. Please see a recent issue for correct formatting.
Author Corrections
The Author Correction section provides a means of correcting
errors of omission (e.g., author names or citations) and errors
of a scientific nature that do not alter the overall basic results or
conclusions of a published article (e.g., an incorrect unit of
measurement or order of magnitude used throughout, con-
tamination of one of numerous cultures, or misidentification
of a mutant strain, causing erroneous data for only a [noncrit-
ical] portion of the study). Note that the addition of newdata is
not permitted.
For corrections of a scientific nature or issues involving au-
thorship, including contributions anduse or ownership of data
and/ormaterials, all disputing partiesmust agree, inwriting, to
publication of the Correction. For omission of an author’s
name, letters must be signed by the authors of the article and
the author whose name was omitted. The editor who handled
the article will be consulted if necessary.
Submit an Author Correction via the eJP online manuscript
submission and peer review system (see “Submission, Review,
and Publication Processes”). Select Author Correction as the
manuscript type. In the Abstract section of the submission
form (a required field), put “Not Applicable.” Upload the text
of your Author Correction as a Microsoft Word file. Please see
a recent issue for correct formatting. Signed letters of agree-
ment must be supplied as supplemental material not for pub-
lication (scanned PDF files).
Retractions
Retractions are reserved for major errors or breaches of ethics
that, for example, may call into question the source of the data
or the validity of the results and conclusions of an article. Sub-
mit Retractions via the eJP online manuscript submission and
peer review system (see “Submission, Review, and Publication
Processes”). In the Abstract section of the submission form (a
required field), put “Not Applicable.” Upload the text of your
Retraction as a Microsoft Word file. Letters of agreement
signed by all of the authors must be supplied as supplemental
material not for publication (scanned PDF files). The Retrac-
tionwill be assigned to the editor in chief of the journal, and the
editor who handled the paper and the chairperson of the ASM
Journals Board will be consulted. If all parties agree to the
publication and content of the Retraction, it will be sent to the
Journals Department for publication.
ILLUSTRATIONS AND TABLES
Illustrations
Image manipulation. Digital images submitted for publica-
tion may be inspected by ASM production specialists for any
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manipulations or electronic enhancements that may be con-
sidered to be the result of scientific misconduct based on the
guidelines provided below. Any images/data found to contain
manipulations of concernwill be referred to the editor in chief,
and authors may then be requested to provide their primary
data for comparison with the submitted image file. Investiga-
tion of the concerns may delay publication and may result in
revocation of acceptance and/or additional action by ASM.
Linear adjustments to contrast, brightness, and/or color are
generally acceptable, as long as the measures taken are neces-
sary to view elements that are already present in the data and
the adjustments are applied to the entire image and not just
specific areas. Unacceptable adjustments to images include,
but are not limited to, the removal or deletion, concealment,
duplication (copying and pasting), addition, selective en-
hancement, or repositioning of elements within the image.
Nonlinear adjustments made to images, such as changes to
gamma settings, should be fully disclosed in the figure legends
at the time of submission. In addition, images created by com-
piling multiple files, including noncontiguous portions of the
same image, should clearly distinguish that these multiple files
are not a single image. This can be done by “tooling,” or insert-
ing thin lines, between the individual images.
File types and formats. Illustrations may be continuous-
tone images, line drawings, or composites. Color graphics may
be submitted, but the cost of printing in colormust be borne by
the author. Suggestions about how to reduce costs and ensure
accurate color reproduction are given below.
On initial submission, figuresmay be uploaded as individual
PDF files or combined and uploaded as a single PDF file. Place
each legend in the text file, as well as on the same page with the
figure to assist review. At the modification stage, production-
quality digital filesmust be provided. The legends will be copy-
edited and typeset for final publication and should not be in-
cluded as part of the figure itself at this stage. All graphics
submitted with modified manuscripts must be bitmap, gray-
scale, or in the RGB (preferred) or CMYK color mode. See
“Color illustrations.” Halftone images (those with various
densities or shades) must be grayscale, not bitmap. JCM ac-
cepts TIFF or EPS files but discourages PowerPoint for either
black-and-white or color images.
For instructions on creating acceptable EPS and TIFF files,
refer to the Cadmus digital art website, http://art.cadmus.com
/da/index.jsp. PowerPoint requires users to pay close attention
to the fonts used in their images (see the section on fonts be-
low). If instructions for fonts are not followed exactly, images
prepared for publication are subject to missing characters, im-
properly converted characters, or shifting/obscuring of ele-
ments or text in the figure. For proper font use in PowerPoint
images, refer to the Cadmus digital art website, http://art
.cadmus.com/da/instructions/ppt_disclaimer.jsp. Note that,
due to page composition system requirements, youmust verify
that your PowerPoint files can be converted to PDF without
any errors.
We strongly recommend that before returning theirmod-
ified manuscripts, authors check the acceptability of their
digital images for production by running their files through
Rapid Inspector, a tool provided at the following URL: http:
//rapidinspector.cadmus.com/RapidInspector/zmw/index.jsp.
Rapid Inspector is an easy-to-use,Web-based application that iden-
tifies file characteristics thatmay render the image unusable for pro-
duction. Please note when using Rapid Inspector to check Power-
Point files that there is a known bug in the application that can
occasionally fail PowerPoint Presentation (.pptx) files, even though
the files meet all required production criteria. If you experience this
bug, the issue can be corrected by saving the PowerPoint files as an
older version, PowerPoint 97-2004 Presentation (.ppt), during the
Save As process (use the drop-down format menu and select this
format).Onceyousaveyourfiles as .ppt, theywill passRapid Inspec-
tor if all required production criteria have beenmet.
If you have additional questions about using the Rapid In-
spector preflighting tool, please send an e-mail inquiry to
helpdesk.digitalartsupport@cenveo.com.
Minimumresolution. It is extremely important that a high
enough resolution is used. All separate images that you import
into a figure file must be at the correct resolution before they
are placed. (For instance, placing a 72-dpi image in a 300-dpi
EPS file will not result in the placed image meeting the mini-
mumrequirements for file resolution.)Note, however, that the
higher the resolution, the larger the file and the longer the
upload time. Publication quality will not be improved by using
a resolution higher than the minimum. Minimum resolutions
are as follows:
• 300 dpi for grayscale and color
• 600 dpi for combination art (lettering and images)
• 1,200 dpi for line art
Size. All graphics should be submitted at their intended
publication size; that is, the image uploaded should be 100%
of its print dimensions so that no reduction or enlargement is
necessary. Resolution must be at the required level at the sub-
mitted size. Include only the significant portion of an illustra-
tion. White space must be cropped from the image, and excess
space between panel labels and the image must be eliminated.
• Maximum width for a 1-column figure: 20.6 picas (ca.
8.7 cm)
• Maximum width for a 2-column figure: 42 picas (ca.
17.8 cm)
• Minimumwidth for a 2-column figure: 26 picas (11.1 cm)
• Maximum height for a standard figure: 54.7 picas (ca.
23.2 cm)
• Maximum height for an oversized figure (no running
title): 57.4 picas (ca. 24.3 cm)
Contrast. Illustrations must contain sufficient contrast to
be viewed easily on a monitor or on the printed page.
Labeling and assembly. All final lettering and labelingmust
be incorporated into the figures. On initial submission, illus-
trations should be provided as PDFfiles, with the legends in the
text file and with a legend beneath each image to assist review.
At the modification stage, production-quality digital figure
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files (without legends) must be provided. Put the figure num-
ber well outside the boundaries of the image itself. (Number-
ing may need to be changed at the copyediting stage.) Each
figure must be uploaded as a separate file, and any multipanel
figures must be assembled into one file; i.e., rather than up-
loading a separate file for each panel in a figure, assemble all
panels in one piece and supply them as one file.
Fonts. To avoid font problems, set all type in one of the
following fonts: Arial, Helvetica, Times Roman, European PI,
Mathematical PI, or Symbol. Courier may be used but should
be limited to nucleotide or amino acid sequences, where a non-
proportional (monospace) font is required. All fonts other
than these must be converted to paths (or outlines) in the ap-
plication with which they were created. For proper font use in
PowerPoint images, refer to the Cadmus digital art website,
http://art.cadmus.com/da/instructions/ppt_disclaimer.jsp.
Color illustrations. Color costs must be borne by the au-
thor. See “Publication Fees.” All figures submitted in color
will be processed as color. Adherence to the following guide-
lines will help tominimize costs and to ensure color reproduc-
tion that is as accurate as possible.
The final online version is considered the version of record
for JCM and all other ASM journals. To maximize online re-
production, color illustrations should be supplied in the RGB
color mode as either (i) RGB TIFF images with a resolution of
at least 300 pixels per inch (raster files, consisting of pixels) or
(ii) Illustrator-compatible EPS files with RGB color elements
(vector files, consisting of lines, fonts, fills, and images). CMYK
files are also accepted. Other than in color space, CMYK files
must meet the same production criteria as RGB files. The RGB
color space is the native color space of computer monitors and
of most of the equipment and software used to capture scien-
tific data, and it can display a wider range of colors (especially
bright fluorescent hues) than the CMYK (cyan, magenta, yel-
low, black) color space used by print devices that put ink (or
toner) on paper. For the print version (and reprints), ASM’s
print provider will automatically create CMYK versions of
color illustrations from the supplied RGB versions. Color in
the print journal may not match that in the online journal of
record because of the smaller range of colors capable of being
reproduced by CMYK inks on a printing press. For additional
information on RGB versus CMYK color, refer to the Cadmus
digital art site, http://art.cadmus.com/da/guidelines_rgb.jsp.
Drawings
Submit graphs, charts, complicated chemical or mathematical
formulas, diagrams, and other drawings as finished products
not requiring additional artwork or typesetting. All elements,
including letters, numbers, and symbols, must be easily read-
able, and both axes of a graph must be labeled. Keep in mind
that the journal is published both in print and online and that
the same electronic files submitted by the authors are used to
produce both.
When creating line art, please use the following guidelines:
(i) All art must be submitted at its intended publication
size. For acceptable dimensions, see “Size,” above.
(ii) Avoid using screens (i.e., shading) in line art. It can be
difficult and time-consuming to reproduce these images with-
out moire´ patterns. Various pattern backgrounds are prefera-
ble to screens as long as the patterns are not imported from
another application. If you must use images containing
screens,
(a) Generate the image at line screens of 85 lines per inch
or less.
(b) When applying multiple shades of gray, differentiate
the gray levels by at least 20%.
(c) Never use levels of gray below 5% or above 95%, as
they are likely to fade out or become totally black when
output.
(iii) Use thick, solid lines that are no finer than 1 point in
thickness.
(iv) No type should be smaller than 6 points at the final
publication size.
(v) Avoid layering type directly over shaded or textured
areas.
(vi) Avoid the use of reversed type (white lettering on a black
background).
(vii) Avoid heavy letters, which tend to close up, and un-
usual symbols, which the printer may not be able to reproduce
in the legend.
(viii) If colors are used, avoid using similar shades of the
same color and avoid very light colors.
In figure ordinate and abscissa scales (aswell as table column
headings), avoid the ambiguous use of numbers with expo-
nents. Usually, it is preferable to use the appropriate Syste`me
International d’Unite´s (SI) symbols ( for 106, m for 103, k
for 103, and M for 106, etc.). Thus, a representation of 20,000
cpm on a figure ordinate should be made by the number 20
accompanied by the label kcpm. A complete listing of SI sym-
bols can be found in the International Union of Pure and Ap-
plied Chemistry (IUPAC) publication Quantities, Units and
Symbols in Physical Chemistry, 3rd ed. (RSC Publishing, Cam-
bridge, United Kingdom, 2011); an abbreviated list is available
at http://old.iupac.org/reports/1993/homann/index.html.
When powers of 10 must be used, the journal requires that
the exponent power be associated with the number shown. In
representing 20,000 cells per ml, the numeral of the ordinate
should be “2” and the label should be “104 cells per ml” (not
“cells per ml  104”). Likewise, an enzyme activity of 0.06
U/ml might be shown as 6 accompanied by the label 102
U/ml. The preferred designation is 60 mU/ml (milliunits per
milliliter).
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Presentation of Nucleic Acid Sequences
Long nucleic acid sequencesmust be presented as figures in the
following format to conserve space. Print the sequence in lines
of approximately 100 to 120 nucleotides in a nonproportional
(monospace) font that is easily legible when published with a
line length of 6 inches (ca. 15.2 cm). If possible, lines of nucleic
acid sequence should be further subdivided into blocks of 10 or
20 nucleotides by spaces within the sequence or by marks
above it. Uppercase and lowercase letters may be used to des-
ignate the exon-intron structure or transcribed regions, etc., if
the lowercase letters remain legible at a 6-inch (ca. 15.2-cm)
line length. Number the sequence line by line; place numerals
representing the first base of each line to the left of the lines.
Minimize spacing between lines of sequence, leaving room
only for annotation of the sequence. Annotation may include
boldface, underlining, brackets, and boxes, etc. Encoded
amino acid sequences may be presented, if necessary, immedi-
ately above or below the first nucleotide of each codon, by
using the single-letter amino acid symbols. Comparisons of
multiple nucleic acid sequences should conform as nearly as
possible to the same format.
Figure Legends
On initial submission, each legend should be placed in the text
file and be incorporated into the image file beneath the figure
to assist review.
Legends should provide enough information so that the fig-
ure is understandable without frequent reference to the text.
However, detailed experimental methodsmust be described in
the Materials and Methods section, not in a figure legend. A
method that is unique to one of several experiments may be
reported in a legend only if the discussion is very brief (one or
two sentences). Define all symbols used in the figure and define
all abbreviations that are not used in the text.
Tables
Tables that contain artwork, chemical structures, or shading
must be submitted as illustrations in an acceptable format at
the modification stage. The preferred format for regular tables
is Microsoft Word; however, WordPerfect and Acrobat PDF
are also acceptable. Note that a straight Excel file is not cur-
rently an acceptable format. Excel files must be either embed-
ded in aWord orWordPerfect document or converted to PDF
before being uploaded.
Tables should be formatted as follows. Arrange the data so
that columns of like material read down, not across. The
headings should be sufficiently clear so that themeaning of the
data is understandable without reference to the text. See the
“Abbreviations” section of these Instructions for those that
should be used in tables. Explanatory footnotes are acceptable,
but more-extensive table “legends” are not. Footnotes should
not include detailed descriptions of the experiment. Tables
must include enough information to warrant table format;
those with fewer than six pieces of data will be incorporated
into the text by the copy editor. Table 1 is an example of a
well-constructed table.
NOMENCLATURE
Chemical and Biochemical Nomenclature
The recognized authority for the names of chemical com-
pounds is Chemical Abstracts (CAS; http://www.cas.org/) and
its indexes.TheMerck Index, 15th ed. (RSCBooks, Cambridge,
UK, 2013), is also an excellent source. For biochemical termi-
nology, including abbreviations and symbols, consult Biochemi-
cal Nomenclature andRelatedDocuments (Portland Press, Lon-
don, United Kingdom, 1992) available at http://www.chem
.qmul.ac.uk/iupac/bibliog/white.html, and the instructions to
authors of the Journal of Biological Chemistry and the Archives
of Biochemistry and Biophysics.
Do not express molecular weight in daltons; molecular
weight is a unitless ratio. Molecular mass is expressed in dal-
tons.
For enzymes, use the recommended (trivial) name assigned
by theNomenclatureCommittee of the InternationalUnion of
Biochemistry (IUB) as described in EnzymeNomenclature (Ac-
ademic Press, Inc., New York, NY, 1992) and its supplements
and at http://www.chem.qmul.ac.uk/iubmb/enzyme/. If a
nonrecommended name is used, place the proper (trivial)
name in parentheses at first use in the abstract and text. Use
the EC number when one has been assigned. Authors of pa-
pers describing enzymological studies should review the stan-
dardsof theSTRENDACommission for informationrequired for
adequate description of experimental conditions and for report-
ing enzyme activity data (http://www.beilstein-institut.de/en
/projects/strenda/guidelines).
For nomenclature of restriction enzymes, DNA methyl-
transferases, homing endonucleases, and their genes, refer to
the article by Roberts et al. (Nucleic Acids Res 31:1805–1812,
2003).
Drugs
Whenever possible, use generic names of drugs; the use of trade
names is not permitted.
Nomenclature of Microorganisms
Binary names, consisting of a generic name and a specific epi-
thet (e.g., Escherichia coli), must be used for all microorgan-
isms. Names of categories at or above the genus level may be
used alone, but specific and subspecific epithets may not. A
TABLE 1 Distribution of protein and ATPase in fractions of dialyzed
membranesa
Membrane Fraction
ATPase
U/mg of protein Total U
Control Depleted membrane 0.036 2.3
Concentrated supernatant 0.134 4.82
E1 treated Depleted membrane 0.034 1.98
Concentrated supernatant 0.11 4.6
a Specific activities of ATPase of nondepleted membranes from control and treated
bacteria were 0.21 and 0.20, respectively.
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specific epithet must be preceded by a generic name, written
out in full the first time it is used in a paper. Thereafter, the
generic name should be abbreviated to the initial capital letter
(e.g., E. coli), provided there can be no confusion with other
genera used in the paper. Names of all taxa (kingdoms, phyla,
classes, orders, families, genera, species, and subspecies) are
printed in italics and should be italicized in the manuscript;
strain designations and numbers are not. Vernacular (com-
mon) names should be in lowercase roman type (e.g., strepto-
coccus, brucella). For Salmonella, genus, species, and subspe-
cies names should be rendered in standard form: Salmonella
enterica at first use, S. enterica thereafter; Salmonella enterica
subsp. arizonae at first use, S. enterica subsp. arizonae thereaf-
ter. Names of serovars should be in roman type with the first
letter capitalized: Salmonella enterica serovar Typhimurium.
After the first use, the serovar may also be given without a
species name: Salmonella Typhimurium, S. Typhimurium, or
Salmonella serovar Typhimurium. For other information re-
garding serovar designations, seeAntigenic Formulae of the Sal-
monella Serovars, 9th ed. (P. A. D. Grimont and F.-X. Weill,
WHO Collaborating Centre for Reference and Research on
Salmonella, Institut Pasteur, Paris, France, 2007; see http:
//www.pasteur.fr/ip/portal/action/WebdriveActionEvent/oid/
01s-000036-089). For a summary of the current standards for
Salmonella nomenclature and the Kaufmann-White criteria,
see the article by Brenner et al. (J ClinMicrobiol 38:2465–2467,
2000), the opinion of the Judicial Commission of the Interna-
tional Committee on Systematics of Prokaryotes (Int J Syst
EvolMicrobiol 55:519–520, 2005), and the article by Tindall et
al. (Int J Syst Evol Microbiol 55:521–524, 2005).
The spelling of bacterial names should follow the Approved
Lists of Bacterial Names (Amended) & Index of the Bacterial and
Yeast Nomenclatural Changes (V. B. D. Skerman et al., ed.,
American Society forMicrobiology,Washington, DC, 1989) and
the validation lists and notification lists published in the
International Journal of Systematic and Evolutionary Micro-
biology (formerly the International Journal of Systematic Bacte-
riology) since January 1989. In addition, two sites on the World
WideWeb list currentapprovedbacterialnames:ProkaryoticNo-
menclature Up-to-Date (http://www.dsmz.de/bacterial-diversity
/prokaryotic-nomenclature-up-to-date.html) and List of Pro-
karyotic Names with Standing in Nomenclature (http://www
.bacterio.net/). If there is reason to use a name that does not
have standing in nomenclature, the name should be enclosed
in quotationmarks in the title and at its first use in the abstract
and the text and an appropriate statement concerning the no-
menclatural status of the name should be made in the text.
“Candidatus” species should always be set in quotation marks.
For guidelines regarding newnames and descriptions of new
genera and species, see the articles by Tindall (Int J Syst Bacte-
riol 49:1309–1312, 1999) and Stackebrandt et al. (Int J Syst
Evol Microbiol 52:1043–1047, 2002). To validate new names
and/or combinations, authors must submit three copies of
their published article to the International Journal of Systematic
and Evolutionary Microbiology.
It is recommended that a strain be deposited in at least two
recognized culture collections in different countries when that
strain is necessary for the description of a new taxon (Int J Syst
Evol Microbiol 50:2239–2244, 2000).
Since the classification of fungi is not complete, it is the
responsibility of the author to determine the accepted bino-
mial for a given organism. Sources for these names include
The Yeasts: a Taxonomic Study, 5th ed. (C. P. Kurtzman, J. W.
Fell, and T. Boekhout, ed., Elsevier Science, Amsterdam,
Netherlands, 2011), and Dictionary of the Fungi, 10th ed.
(P.M. Kirk, P. F. Cannon, D.W.Minter, and J. A. Stalpers, ed.,
CABI International, Wallingford, Oxfordshire, United King-
dom, 2008); see also http://www.speciesfungorum.org/Names
/Fundic.asp.
Names used for viruses should be those approved by the
International Committee on Taxonomy of Viruses (ICTV)
and reported on the ICTV Virus Taxonomy website (http:
//www.ictvonline.org/index.asp). In addition, the recommen-
dations of the ICTV regarding the use of species names should
generally be followed: when the entire species is discussed as a
taxonomic entity, the species name, as with other taxa, is italic
and has the first letter and any proper nouns capitalized (e.g.,
Tobacco mosaic virus, Murray Valley encephalitis virus). When
the behavior or manipulation of individual viruses is dis-
cussed, the vernacular (e.g., tobaccomosaic virus,Murray Val-
ley encephalitis virus) should be used. If desired, synonyms
may be added parenthetically when the name is first men-
tioned. Approved generic (or group) and family names may
also be used.
Microorganisms, viruses, and plasmids should be given des-
ignations consisting of letters and serial numbers. It is gener-
ally advisable to include aworker’s initials or a descriptive sym-
bol of locale or laboratory, etc., in the designation. Each new
strain, mutant, isolate, or derivative should be given a new
(serial) designation. This designation should be distinct from
those of the genotype and phenotype, and italicized genotypic
and phenotypic symbols should not be included. Plasmids are
named with a lowercase “p” followed by the designation in
uppercase letters and numbers. To avoid the use of the same
designation as that of awidely used strain or plasmid, check the
designation against a publication database such as Medline.
Genetic Nomenclature
To facilitate accurate communication, it is important that stan-
dard genetic nomenclature beusedwhenever possible and that
deviationsorproposals fornewnaming systemsbe endorsed
by an appropriate authoritative body. Review and/or publi-
cation of submittedmanuscripts that contain new or nonstan-
dard nomenclature may be delayed by the editor or the Jour-
nals Department so that they may be reviewed.
Bacteria. The genetic properties of bacteria are described in
terms of phenotypes and genotypes. The phenotype describes
the observable properties of an organism. The genotype refers
to the genetic constitution of an organism, usually in reference
to some standard wild type. Use the recommendations of De-
merec et al. (Genetics 54:61–64, 1966) as a guide to the use of
these terms. If your manuscript contains information includ-
ing genetic nomenclature, please refer to the Instructions to
Authors of the Journal of Bacteriology.
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“Mutant” versus “mutation.” Keep in mind the distinc-
tion between a mutation (an alteration of the primary se-
quence of the genetic material) and amutant (a strain carrying
one ormoremutations). Onemay speak about themapping of
a mutation, but one cannot map a mutant. Likewise, a mutant
has no genetic locus, only a phenotype.
“Homology” versus “similarity.” For use of terms that de-
scribe relationships between genes, consult the articles by
Theissen (Nature 415:741, 2002) and Fitch (Trends Genet 16:
227–231, 2000). “Homology” implies a relationship between
genes that have a common evolutionary origin; partial homol-
ogy is not recognized. When sequence comparisons are dis-
cussed, it is more appropriate to use the term “percent se-
quence similarity” or “percent sequence identity,” as
appropriate.
Tetracycline resistance determinants. The nomenclature
for tetracycline resistance determinants is based on the pro-
posal of Levy et al. (Antimicrob Agents Chemother 43:1523–
1524, 1999). The style for such determinants is, e.g., Tet B; the
space helps distinguish the determinant designation from that
for phenotypes and proteins (TetB). The above-referenced ar-
ticle also gives the correct format for genes, proteins, and de-
terminants in this family.
Locus tags. Locus tags are systematic, unique identifiers
that are assigned to each gene in GenBank. All genes men-
tioned in a manuscript should be traceable to their sequences
by the reader, and locus tags may be used for this purpose in
manuscripts to identify uncharacterized genes. In addition,
authors should check GenBank to make sure that they are us-
ing the correct, up-to-date format for locus tags (e.g., upper-
case versus lowercase letters and the presence or absence of an
underscore, etc.). Locus tag formats vary between different or-
ganisms and also may be updated for a given organism, so it is
important to check GenBank at the time of manuscript prep-
aration.
Viruses. The genetic nomenclature for viruses differs from
that for bacteria. Inmost instances, viruses have no phenotype,
since they have no metabolism outside host cells. Therefore,
distinctions betweenphenotype and genotype cannot bemade.
Superscripts are used to indicate hybrid genomes. Genetic
symbols may be one, two, or three letters.
Eukaryotes. FlyBase (http://flybase.org/) is the genetic no-
menclature authority for Drosophila melanogaster. WormBase
(http://www.wormbase.org/#01-23-6) is the genetic nomen-
clature authority for Caenorhabditis elegans. When naming
genes for Aspergillus species, the nomenclature guidelines
posted at http://www.aspergillus.org.uk/indexhome.htm?
secure/sequence_info/nomenclature.htm should be fol-
lowed, and the Aspergillus Genome Database (http://www
.aspgd.org/) should be searched to ensure that any new name is
not already in use. The SaccharomycesGenomeDatabase (http:
//www.yeastgenome.org/) and the Candida Genome Database
http://www.candidagenome.org/) are authorities for Saccharo-
myces cerevisiae and Candida albicans genetic nomenclature,
respectively. For more information about the genetic no-
menclature of eukaryotes, see the Instructions to Authors for
Eukaryotic Cell and Molecular and Cellular Biology.
ABBREVIATIONS AND CONVENTIONS
Verb Tense
ASM strongly recommends that for clarity you use the past tense
to narrate particular events in the past, including the procedures,
observations, and data of the study that you are reporting. Use
the present tense for your own general conclusions, the con-
clusions of previous researchers, and generally accepted facts.
Thus,most of the abstract,Materials andMethods, andResults
will be in the past tense, andmost of the introduction and some
of the Discussion will be in the present tense.
Be aware that it may be necessary to vary the tense in a single
sentence. For example, it is correct to say “White (30) demon-
strated that XYZ cells grow at pH 6.8,” “Figure 2 shows that
ABC cells failed to grow at room temperature,” and “Air was
removed from the chamber and the mice died, which proves
thatmice require air.” In reporting statistics and calculations, it
is correct to say “The values for the ABC cells are statistically
significant, indicating that the drug inhibited . . .”
For an in-depth discussion of tense in scientific writing, see
How ToWrite and Publish a Scientific Paper, 7th ed.
Abbreviations
General. Abbreviations should be used as an aid to the reader,
rather than as a convenience for the author, and therefore their
use should be limited.Abbreviations other than those recom-
mended by the IUPAC-IUB (Biochemical Nomenclature and
Related Documents, 1992) should be used only when a case can
be made for necessity, such as in tables and figures.
It is often possible to use pronouns or to paraphrase a long
word after its first use (e.g., “the drug” or “the substrate”).
Standard chemical symbols and trivial names or their symbols
(folate, Ala, and Leu, etc.) may also be used.
Define each abbreviation and introduce it in parentheses the
first time it is used; e.g., “Cultureswere grown inEagleminimal
essential medium (MEM).” Generally, eliminate abbreviations
that are not used at least three times in the text (including
tables and figure legends).
Not requiring introduction. In addition to abbrevia-
tions for Syste`me International d’Unite´s (SI) units of mea-
surement, other common units (e.g., bp, kb, and Da), and
chemical symbols for the elements, the following should be
used without definition in the title, abstract, text, figure leg-
ends, and tables:
DNA (deoxyribonucleic acid)
cDNA (complementary DNA)
RNA (ribonucleic acid)
cRNA (complementary RNA)
RNase (ribonuclease)
DNase (deoxyribonuclease)
rRNA (ribosomal RNA)
mRNA (messenger RNA)
tRNA (transfer RNA)
AMP, ADP, ATP, dAMP,
ddATP, and GTP, etc. (for the
respective 5 phosphates
of adenosine and other
nucleosides) (add 2-,
3-, or 5- when needed for
contrast)
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ATPase and dGTPase, etc.
(adenosine triphosphatase
and deoxyguanosine
triphosphatase, etc.)
NAD (nicotinamide adenine
dinucleotide)
NAD (nicotinamide adenine
dinucleotide, oxidized)
NADH (nicotinamide adenine
dinucleotide, reduced)
NADP (nicotinamide adenine
dinucleotide phosphate)
NADPH (nicotinamide adenine
dinucleotide phosphate,
reduced)
NADP (nicotinamide adenine
dinucleotide phosphate,
oxidized)
poly(A) and poly(dT), etc.
(polyadenylic acid and
polydeoxythymidylic acid,
etc.)
oligo(dT), etc. (oligodeoxy-
thymidylic acid, etc.)
UV (ultraviolet)
PFU (plaque-forming units)
CFU (colony-forming units)
MIC (minimal inhibitory
concentration)
Tris (tris[hydroxymethyl]
aminomethane)
DEAE (diethylaminoethyl)
EDTA (ethylenediamine-
tetraacetic acid)
EGTA (ethylene glycol-bis[-
aminoethyl ether]-N,N,N,N-
tetraacetic acid)
HEPES (N-2-hydroxyethyl-
piperazine-N-2-
ethanesulfonic acid)
PCR (polymerase chain reaction)
AIDS (acquired immuno-
deficiency syndrome)
Abbreviations for cell lines (e.g., HeLa) also need not be de-
fined.
The following abbreviations should be used without defini-
tion in tables:
amt (amount)
approx (approximately)
avg (average)
concn (concentration)
diam (diameter)
expt (experiment)
exptl (experimental)
ht (height)
mo (month)
mol wt (molecular weight)
no. (number)
prepn (preparation)
SD (standard deviation)
SE (standard error)
SEM (standard error of the
mean)
sp act (specific activity)
sp gr (specific gravity)
temp (temperature)
tr (trace)
vol (volume)
vs (versus)
wk (week)
wt (weight)
yr (year)
Drugs. Should an author decide to abbreviate the names of
antimicrobial agents in a manuscript, the following standard
abbreviations are strongly recommended.
Antibacterial agents. Use the indicated abbreviations for
the following antibacterial agents.
amikacin (AMK)
amoxicillin (AMX)
amoxicillin-clavulanic acid (AMC)
ampicillin (AMP)
ampicillin-sulbactam (SAM)
azithromycin (AZM)
azlocillin (AZL)
aztreonam (ATM)
carbenicillin (CAR)
cefaclor (CEC)
cefadroxil (CFR)
cefamandole (FAM)
cefazolin (CFZ)
cefdinir (CDR)
cefditoren (CDN)
cefepime (FEP)
cefetamet (FET)
cefixime (CFM)
cefmetazole (CMZ)
cefonicid (CID)
cefoperazone (CFP)
cefotaxime (CTX)
cefotetan (CTT)
cefoxitin (FOX)
cefpodoxime (CPD)
cefprozil (CPR)
ceftazidime (CAZ)
ceftibuten (CTB)
ceftizoxime (ZOX)
ceftriaxone (CRO)
cefuroxime (axetil) and
cefuroxime (sodium) (CXM)
cephalexin (LEX)
cephalothin (CEF)
cephapirin (HAP)
cephradine (RAD)
chloramphenicol (CHL)
cinoxacin (CIN)
ciprofloxacin (CIP)
clarithromycin (CLR)
clinafloxacin (CLX)
clindamycin (CLI)
daptomycin (DAP)
dicloxacillin (DCX)
dirithromycin (DTM)
doxycycline (DOX)
enoxacin (ENX)
erythromycin (ERY)
fleroxacin (FLE)
fosfomycin (FOF)
gatifloxacin (GAT)
gentamicin (GEN)
grepafloxacin (GRX)
imipenem (IPM)
kanamycin (KAN)
levofloxacin (LVX)
linezolid (LZD)
lomefloxacin (LOM)
loracarbef (LOR)
meropenem (MEM)
methicillin (MET)
mezlocillin (MEZ)
minocycline (MIN)
moxalactam (MOX)
moxifloxacin (MXF)
nafcillin (NAF)
nalidixic acid (NAL)
netilmicin (NET)
nitrofurantoin (NIT)
norfloxacin (NOR)
ofloxacin (OFX)
oxacillin (OXA)
penicillin (PEN)
piperacillin (PIP)
piperacillin-tazobactam (TZP)
quinupristin-dalfopristin
(Synercid) (Q-D)
rifabutin (RFB)
rifampin (RIF)
rifapentine (RFP)
sparfloxacin (SPX)
spectinomycin (SPT)
streptomycin (STR)
teicoplanin (TEC)
telithromycin (TEL)
tetracycline (TET)
ticarcillin (TIC)
ticarcillin-clavulanic acid (TIM)
tobramycin (TOB)
trimethoprim (TMP)
trimethoprim-sulfamethoxazole
(SXT)
trovafloxacin (TVA)
vancomycin (VAN)
-Lactamase inhibitors. Use the indicated abbreviations
for the following -lactamase inhibitors.
clavulanic acid (CLA)
sulbactam (SUL)
tazobactam (TZB)
Antifungal agents. Use the indicated abbreviations for the
following antifungal agents.
amphotericin B (AMB)
clotrimazole (CLT)
flucytosine (5FC)
fluconazole (FLC)
itraconazole (ITC)
ketoconazole (KTC)
nystatin (NYT)
terbinafine (TRB)
voriconazole (VRC)
Antiviral agents. Use the indicated abbreviations for the
following antiviral agents.
acyclovir (ACV)
cidofovir (CDV)
famciclovir (FCV)
foscarnet (FOS)
ganciclovir (GCV)
penciclovir (PCV)
valacyclovir (VCV)
zidovudine (AZT)
Reporting Numerical Data
Standard metric units are used for reporting length, weight, and
volume. For these units and formolarity, use the prefixesm,, n,
and p for 103, 106, 109, and 1012, respectively. Likewise,
use the prefix k for 103. Avoid compound prefixes such as m
or . Use g/ml or g/g in place of the ambiguous ppm.
Units of temperature are presented as follows: 37°C or 324 K.
When fractions are used to express units such as enzymatic
activities, it is preferable to use whole units, such as “g” or
“min,” in the denominator instead of fractional or multiple
units, such asg or 10min. For example, “pmol/min” is prefera-
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ble to “nmol/10min,” and “mol/g” is preferable to “nmol/g.”
It is also preferable that an unambiguous form, such as exponen-
tial notation, be used; for example, “mol g1min1” is prefera-
ble to “mol/g/min.” Always report numerical data in the appro-
priate SI units.
Representation of data as accurate to more than two signif-
icant figures must be justified by presentation of appropriate
statistical analyses.
For a review of some common errors associatedwith statistical
analyses and reports, plus guidelines on how to avoid them, see
the articles by Olsen (Infect Immun 71:6689–6692, 2003; Infect
Immun 82:916–920, 2014).
For a review of basic statistical considerations for virology
experiments, see the article by Richardson and Overbaugh
(J Virol 79:669–676, 2005).
Statistics
Statistical analysis of data is a crucial component of scientific
publication. Authors who are unsure of proper statistical anal-
ysis should have their manuscripts checked by a qualified stat-
istician.
The following is a list of important items that must be con-
sidered before manuscript submission. Deficiencies in any of
these areas may delay review and/or publication.
(i) Statistical analyses were performed on all quantitative
data regardless of how significant the differences look in the
tables or figures.
(ii) Data were appropriately analyzed as parametric (nor-
mally distributed) or nonparametric data.
(iii) Parametric and nonparametric data are presented ap-
propriately. Means and standard deviations or standard errors
are appropriate means of presenting data analyzed by para-
metric analyses (i.e., t test and analysis of variance [ANOVA]),
but only medians and surrounding levels (quartiles, quin-
tiles, and 10th and 90th percentiles, etc.) are appropriate for non-
parametric statistics (Mann-Whitney test andKruskal-Wallis test,
etc.). Means have nomeaning in nonparametric analyses.
(iv) For any data in which there are more than two compar-
isons (i.e., between one control andmore than one experimen-
tal group), an analysis must be done for multigroup compari-
sons. Such an analysis would usually be an ANOVA for
parametric data or a Kruskal-Wallis test for nonparametric
data. t tests cannot be used when more than two groups are
being compared (except as indicated below). Failure to use
multigroup tests generates type 1 errors: concluding that two
data sets within the overall data set being compared are differ-
ent when in fact they are not. Exception: some statisticians
argue that two-group comparisons can be used onmultigroup
data if the expected outcomes are appropriately anticipated
before the experiment. For example, data generated by individ-
ually testing two unrelated factors for their effects on a target
with only a single, untreated target as a control could be ap-
propriately analyzed by t tests instead of ANOVA.
(v) For all appropriate multigroup comparisons, two P val-
ues must be generated and provided in the manuscript. The
main P value applies to the overall data set and indicates that
within that data set at least two groups differ from each other.
The overall P value does not indicate which two groups are
different. The main P value and the overall P value should be
computed by using a post hoc test. For ANOVA, these post hoc
tests are usually Dunnett’s test (used to compare multiple ex-
perimental groups to a single control), the Fisher protected
least significant difference (PLSD) test, the Tukey-Kramer test,
and the Games-Howell test. Others may be used. Note that
each post hoc test has certain underlying assumptions that may
not be applicable to the data under analysis. For a Kruskal-
Wallis nonparametric ANOVA, the Dunn procedure is appro-
priate to generate P values for two-group comparisons.
(vi) Data presented as endpoints (i.e., LD50 and ID50, etc.)
contain both the calculated value and a confidence interval
with a statistical significance associated with it (95%, 99%, or
similar confidence interval), calculated by logit or probit anal-
ysis. Simple LD50 values, such as Reed-Muench calculations,
may not be used alone.
(vii) When samples are taken multiple times from one ex-
perimental entity (i.e., multiple serum samples from one ani-
mal, gross pathology scoresmeasured for the same animal over
time or growth curves, etc.), one cannot use analyses such as t
tests, ANOVA, or the Mann-Whitney test, etc., because these
tests assume that each measure is independent. An entity with
a high score on day 1 is more likely to have a high score on day
2 than is an entity with a low score. It is likely that some expert
statistical help will be needed for these situations, usually in-
volving regression analysis or survival analysis, etc.
(viii) Statistical significance and biological significance are
not the same. There is nothing magical about a P value of 0.05.
When results from large sample sizes are compared, a P value
of0.05 will often be obtained, as P value is a function of both
sample size and effect size. If sample sizes are large, thenmore-
rigorous (i.e., smaller) P values may be desirable. If sample
sizes are small, P values of	0.05 may still be important. There
should be both statistical and biological significance to the re-
sults and conclusions in the manuscript.
For a review of some common errors associated with statis-
tical analyses and reports, plus guidelines on how to avoid them,
see the articles by Olsen (Infect Immun 71:6689–6692, 2003; In-
fect Immun 82:916–920, 2014).
For a review of basic statistical considerations for virology
experiments, see the article by Richardson and Overbaugh
(J Virol 79:669–676, 2005).
Isotopically Labeled Compounds
For simplemolecules, labeling is indicated in the chemical for-
mula (e.g., 14CO2,
3H2O, and H2
35SO4). Brackets are not used
when the isotopic symbol is attached to the name of a com-
pound that in its natural state does not contain the element
(e.g., 32S-ATP) or to aword that is not a specific chemical name
(e.g., 131I-labeled protein, 14C-amino acids, and 3H-ligands).
For specific chemicals, the symbol for the isotope intro-
duced is placed in square brackets directly preceding the part of
the name that describes the labeled entity. Note that configu-
ration symbols andmodifiers precede the isotopic symbol. The
following examples illustrate correct usage:
[14C]urea
L-[methyl-14C]methionine
[2,3-3H]serine
[
-14C]lysine
UDP-[U-14C]glucose
E. coli [32P]DNA
fructose 1,6-[1-32P]bisphosphate
[-32P]ATP
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5. ANEXOS 
Anexo 1. CBQCA_MRSA online database*  
(http://mlva.u-psud.fr/mlvav4/genotyping/view.php?b=CBQCA_MRSA/ [CBQCA_MRSA database]) 
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a, TrSa214, TrSa152, TrSa150, and TrSa134 are control strains. 
b, ECU stands for Ecuador, FR stands for France. 
c, HVQ stands for Hospital Vozandes Quito. 
*In all the table, except in loci data, 1 stands for presence and 0 for absence. In loci data numbers 
represent VNTR repeats. 
 
 
 
 
 
 
S
tr
a
in
 i
d
a
 
S
p
e
c
ie
s
 
Y
e
a
r 
o
f 
is
o
la
ti
o
n
 
C
o
u
n
tr
y
b
 
H
V
Q
 S
a
m
p
le
 i
d
c
 
H
o
s
t 
Is
o
la
te
d
 f
ro
m
 
S
k
in
 a
n
d
 s
o
ft
 t
is
s
u
e
 
P
o
s
t-
s
u
rg
ic
a
l 
w
o
u
n
d
 
T
ra
c
h
e
a
l-
b
ro
n
c
h
ia
l 
B
lo
o
d
 
B
o
n
e
 m
a
rr
o
w
 
O
th
e
rs
 
P
V
L
 (
L
u
k
S
/F
-P
V
) 
c
c
r 
c
o
m
p
le
x
 
m
e
c
 c
o
m
p
le
x
 
S
C
C
m
e
c
 
S
A
0
1
2
2
/2
4
_
0
1
 
S
A
0
2
6
6
/8
1
_
0
1
 
S
A
0
3
1
1
 
S
A
0
7
0
4
/6
7
_
0
1
 
S
A
0
9
0
6
 
S
A
1
1
3
2
/6
3
_
0
1
 
S
A
1
1
9
4
 
S
A
1
2
1
3
 
S
A
1
2
9
1
 
S
A
1
4
2
5
 
S
A
1
7
2
9
 
S
A
1
7
5
6
 
S
A
1
8
6
6
 
S
A
2
0
3
9
 
R
e
la
te
d
n
e
s
s
_
1
0
lo
c
 
D
is
ta
n
c
e
_
1
0
lo
c
i 
R
e
la
te
d
n
e
s
s
_
1
4
lo
c
i 
D
is
ta
n
c
e
_
1
4
lo
c
i 
135 
M
R
S
A
 
2
0
1
0
 
E
C
U
 
8
9
6
 
H
u
m
a
n
 
R
ig
h
t 
a
n
k
le
 
1 0 0 0 0 0 0 2.3.5 B NT 10 4 1 4 3 3 7 5.5 4 2 3 2 3 3 X X ST5 5 
138 
M
R
S
A
 
2
0
1
0
 
E
C
U
 
1
0
4
6
 
H
u
m
a
n
 
E
lb
o
w
 a
b
s
c
e
s
s
 
1 0 0 0 0 0 0 2.3 A.B NT 10 5 2 6 2 1 3 3 1 3 1 2 3 3 ST8 1 ST8 1 
141 
M
R
S
A
 
2
0
1
0
 
E
C
U
 
5
1
3
 
H
u
m
a
n
 
B
lo
o
d
 
0 0 0 1 0 0 1 2 A.B NT 10 5 2 6 2 1 3 3 1 3 1 2 3 3 ST8 1 ST8 1 
142 
M
R
S
A
 
2
0
1
0
 
E
C
U
 
5
4
2
 
H
u
m
a
n
 
V
u
lv
a
r 
p
u
s
tu
le
s
 
1 0 0 0 0 0 1 2 B IV 10 4 2 6 2 2 3 3 1 3 1 2 3 3 ST8 1 ST8 1 
143 
M
R
S
A
 
2
0
1
0
 
E
C
U
 
5
1
1
 
H
u
m
a
n
 
B
lo
o
d
 
0 0 0 1 0 0 1 2 B IV 10 6 2 6 2 1 3 3 1 3 1 2 3 3 ST8 2 ST8 2 
147 
M
R
S
A
 
2
0
1
0
 
E
C
U
 
7
2
5
 
H
u
m
a
n
 
G
lu
te
u
s
 
a
b
s
c
e
s
s
 
1 0 0 0 0 0 0 2.5 B IVh 10 4 2 6 2 2 3 3 1 3 1 2 3 3 ST8 1 ST8 1 
71 
Anexo 2. Ejemplo de una publicación en la revista seleccionada 
JOURNAL OF CLINICAL MICROBIOLOGY, Oct. 2009, p. 3121–3128 Vol. 47, No. 10
0095-1137/09/$08.000 doi:10.1128/JCM.00267-09
Copyright © 2009, American Society for Microbiology. All Rights Reserved.
Improved Multiple-Locus Variable-Number Tandem-Repeat Assay for
Staphylococcus aureus Genotyping, Providing a Highly Informative
Technique Together with Strong Phylogenetic Value†
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We describe an improved multiple-locus variable-number tandem-repeat (VNTR) analysis (MLVA) scheme
for genotyping Staphylococcus aureus. We compare its performance to those of multilocus sequence typing
(MLST) and spa typing in a survey of 309 strains. This collection includes 87 epidemic methicillin-resistant S.
aureus (MRSA) strains of the Harmony collection, 75 clinical strains representing the major MLST clonal
complexes (CCs) (50 methicillin-sensitive S. aureus [MSSA] and 25 MRSA), 135 nasal carriage strains (133
MSSA and 2 MRSA), and 13 published S. aureus genome sequences. The results show excellent concordance
between the techniques’ results and demonstrate that the discriminatory power of MLVA is higher than those
of both MLST and spa typing. Two hundred forty-two genotypes are discriminated with 14 VNTR loci (diversity
index, 0.9965; 95% confidence interval, 0.9947 to 0.9984). Using a cutoff value of 45%, 21 clusters are observed,
corresponding to the CCs previously defined by MLST. The variability of the different tandem repeats allows
epidemiological studies, as well as follow-up of the evolution of CCs and the identification of potential
ancestors. The 14 loci can conveniently be analyzed in two steps, based upon a first-line simplified assay
comprising a subset of 10 loci (panel 1) and a second subset of 4 loci (panel 2) that provides higher resolution
when needed. In conclusion, the MLVA scheme proposed here, in combination with available on-line geno-
typing databases (including http://mlva.u-psud.fr/), multiplexing, and automatic sizing, can provide a basis for
almost-real-time large-scale population monitoring of S. aureus.
Staphylococcus aureus is a pathogen of worldwide clinical
significance. For this reason, it is the subject of intensive in-
vestigations in terms of virulence and drug resistance pheno-
types and, also, population genetics. Although the latter is not
of significant use for short-term patient care, it is essential for
understanding the emergence and spread of new phenotypes.
For instance, it was initially considered most likely that methi-
cillin (meticillin)-resistant variants were appearing only rarely
through the acquisition of a mobile DNA region designated
staphylococcal cassette chromosome mec (SCCmec) and that
these variants were spreading efficiently worldwide (34). How-
ever, the most recent population genetics investigations sug-
gested instead that SCCmec was acquired hundreds of times
independently worldwide and that, as a rule, the geographic
spread of these resistant strains was limited (28, 36). This
knowledge could be produced in the past 10 years due to
sequence-based approaches, mainly multilocus sequence typ-
ing (MLST) analysis, in which approximately 3 kb of coding
genome sequence (or 1/1,000 of the whole genome) are
scanned for polymorphism. MLST has allowed the creation of
shared and high-quality databases which can be easily queried
over the Internet, and this has proved to be highly valuable (7).
However, as the sequences used in MLST schemes evolve
slowly and are highly conserved, the resolution provided by
MLST is too low for the investigation of recent evolution and,
above all, for short-term epidemiological studies. The sequenc-
ing of much larger portions of the genome to increase resolu-
tion can only be used in dedicated research projects analyzing
a limited number of strains (28). Presently, pulsed-field gel
electrophoresis (PFGE) remains the most discriminatory tech-
nique for S. aureus typing, but it allows the constitution of
shared databases only at the national level and is not appro-
priate for population studies (1, 35). There is, consequently,
still a need for a technology as discriminatory as PFGE and as
portable as MLST at a low cost.
Tandemly repeated sequences provide a very valuable
source of polymorphism. Multilocus variable-number tandem-
repeat (VNTR) analysis (MLVA) is now used in genotyping
several bacterial species (26, 48). MLVA typing relies upon a
basic and widespread methodology, the measurement of the
length of DNA fragments. It is not a “pattern”-producing
method, even when run on agarose gels. The genotype, in the
form of a string of numbers corresponding to the number of
repeats at each locus, is highly portable and can be readily
incorporated in large databases (13).
* Corresponding author. Mailing address: Baˆtiment 400, Labora-
toire GPMS, Institut de Ge´ne´tique et Microbiologie, Universite´ Paris
Sud, 91405 Orsay cedex, France. Phone: 33 1 69 15 30 01. Fax: 33 1 69
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† Supplemental material for this article may be found at http://jcm
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VNTRs were proposed years ago to genotype S. aureus iso-
lates, first with a tandem repeat (TR) adjacent to the coagulase
gene coa (12) and later with a single TR present in the S.
aureus protein A (spa) gene (9). Subsequently, new TRs
present in individual genes were analyzed simultaneously to
produce patterns, or “fingerprints” (8, 37). A second level of
TR-associated polymorphisms due to repeat unit variations
was exploited by sequencing TR alleles. The spa gene, provid-
ing a high level of information, is most frequently used. It
allows the relatively correct assignment of isolates to MLST-
defined clonal complexes (CCs) (17, 22, 41), with some occa-
sional exceptions. The resulting data have a limited phyloge-
netic value (28). In order to increase the discriminatory power
and phylogenetic content, an assay called double-locus se-
quence typing (DLST) in which a second TR locus (clfB) is
included has recently been developed (23).
MLVA stricto sensu, in which a repeat copy number is
deduced for each locus, was first applied to S. aureus genotyp-
ing by Hardy et al., using seven members of a class of repeated
elements called staphylococcal interspersed repeat units
(SIRUs) (15, 16). Eleven additional TRs were later identified,
and different combinations were used to improve the assay
(11). Ikawaty et al. recently described an MLVA scheme with
six SIRUs (20) that showed a higher discriminatory power than
MLST and spa typing. However, the clustering only identified
three large clusters of MLVA types and the correlation with
MLST CCs was partial. In a recent work, Schouls et al. con-
firmed that MLVA with as few as eight VNTRs provided
clustering similar to that of spa typing and PFGE, but they did
not demonstrate agreement between MLST complexes and
MLVA complexes with their assay (40).
Although MLVA appears to have the potential to provide a
technique for short-term epidemiological studies that is fast
and reliable in comparison to other techniques, there is still no
consensus on the set of VNTR markers to be used for an
efficient genotyping protocol and, more generally, for the po-
tential use of MLVA for S. aureus typing. Different TRs vary at
different rates, and homoplasy levels at individual VNTRs may
be high. Due to intraspecies genetic variability in S. aureus,
some primer combinations fail to amplify a significant fraction
of the strains. The loci and primers to be used need to be
carefully selected. In the present study, we have investigated
new VNTRs, as well as previously described ones, and we
propose an MLVA genotyping scheme, the MLVA-14 assay,
made up of two complementary panels totaling 14 markers,
which provides an easy and highly informative genotyping as-
say with a strong phylogenetic content. For this purpose, we
analyzed three diverse S. aureus strain collections which were
previously characterized in detail with both MLST and spa
typing.
MATERIALS AND METHODS
Strains. Eighty-seven strains from the Harmony collection (1) were provided
by Alex van Belkum. Twenty-five methicillin-resistant S. aureus (MRSA) carriage
strains were isolated in the Maastricht University Medical Center (MUMC) in
The Netherlands between 2002 and 2006 and comprise five strains each from
MLST CC5, CC8, CC22, CC30, and CC45 (29). Fifty methicillin-sensitive S.
aureus (MSSA) nasal carriage strains were isolated from patients attending their
general practitioner in The Netherlands during 2005 and comprise five strains
each from MLST CC5, CC7, CC8, CC12, CC15, CC22, CC25, CC30, CC45, and
CC51 (6). These 75 strains were previously spa typed (30).
One hundred thirty-five nasal carriage strains, two of which were MRSA, were
isolated from newly employed hospital personnel during their first medical
checkup at a tertiary care hospital in Lausanne, Switzerland, and have been
genotyped using MLST, spa typing, amplified fragment-length polymorphism,
and DLST (39). Reference strain Mu50 was purchased from the Centre de
Ressources Biologiques de l’Institut Pasteur (CRBIP). The Ridom nomenclature
was used to describe the organization of the spa repeats (17).
MLVA. Oligonucleotide primers targeting the 5 and 3 flanking regions of the
selected loci and matching the sequenced genomes of strains COL, MRSA476,
MW2, N315, NCTC8325, JH1, JH9, Newman, USA300 (FPR3757), and USA300
(TCH1516) were used for amplification. Some mismatches existed with the
genomes of strains MRSA252 and RF122. DNA was extracted by using a DNeasy
tissue kit (Qiagen) after treatment of bacteria with lysostaphin (Sigma) at a
concentration of 1 mg/ml. PCRs were performed in 15-l volumes containing 2
ng DNA, 1 PCR buffer, 1.5 mM MgCl2, 1 U Taq DNA polymerase (Qiagen,
Courtaboeuf, France), 200 M of each deoxynucleoside triphosphate, and 0.3
M of each flanking primer (Eurogentec, Angers, France). Amplification was
performed with a PTC 200 thermocycler (Bio-Rad, Marnes-la-Coquette, France)
using the following conditions: initial denaturation cycle for 5 min at 94°C, 35
cycles of denaturation for 30 s at 94°C, annealing for 30 s at various temperatures
(indicated in Table 1), and elongation for 45 s at 72°C plus a final elongation step
for 10 min at 72°C. Three microliters of PCR products was separated in a 2%
agarose gel (Eurogentec, Angers, France). Electrophoresis was performed in
20-cm-long gels made in 0.5 Tris-borate-EDTA buffer (Sigma), run at 8 V/cm.
In each run, the PCR product from reference strain Mu50 was included at least
once. The 100-bp DNA size marker was from MBI Fermentas (Euromedex,
Souffelweyersheim, France). The gels were stained after the run in 0.5 g/ml
ethidium bromide for 15 to 30 min and then rinsed with water and photographed
under UV illumination (Vilber-Lourmat, Marne la Valle´e, France). To prevent
carryover contamination, the different steps of the procedure were performed in
separate rooms with dedicated materials.
In the first phase of the study, the size of the amplicons was measured with the
assistance of BioNumerics 5.1 (Applied-Maths, Sint-Martens-Latem, Belgium),
and the number of repeats was deduced using the Mu50 genome sequence as a
reference. Thereafter, the size of the amplicons was directly estimated by eye
before import and conversion into a character data set in BioNumerics.
Nomenclature and description of MLVA profiles. The repeat lengths and
numbers of repeat units in the different sequenced genomes were determined by
using the Microorganisms Tandem Repeats Database (http://minisatellites.u
-psud.fr) (4, 13, 25). For each locus, the size of the PCR product, S, in the first
sequenced genome (as predicted by in silico analysis of reference strain Mu50
with the primer pair used here), the size of the repeat unit, U, and the corre-
sponding number of repeat units, N, are indicated in Table 1. Amplification of
DNA from reference strain Mu50 produced amplicons of the expected size. The
exact copy number for each allele was calculated as follows: S was subtracted
from the estimated allele size, and the result was divided by U, added to N, and
rounded up to the nearest integer that was distant by less than 0.2. Alleles which
could not be rounded up following this rule were double-checked and eventually
sequenced to confirm the existence of intermediate alleles (0.5) and to establish
the reason for this intermediate size (which may result from small deletions in
the flanking sequence).
The polymorphism index of individual or combined VNTR loci was calculated
using the Hunter-Gaston diversity index (19), an application of Simpson’s index
of diversity (43). Confidence intervals (CI) were calculated as described by
Grundmann et al. (14). The results of using the MLVA-14 assay, with 14 VNTRs
in two panels, to genotype a strain are expressed as its allelic profile, correspond-
ing to the number of repeats at each VNTR in the order Sa0122 (spa), Sa0266
(coa), Sa0311, Sa0704, Sa1132, Sa1194, Sa1291 (SIRU13), Sa1729, Sa1866, and
Sa2039 (panel 1) and Sa0906, Sa1213, Sa1425, and Sa1756 (SIRU15) (panel 2)
(Table 1). The genotype of Mu50, deduced from its genomic sequence, is 10 6 3
4 6 7 4 5 3 3 (panel 1) 3 5 4 2 (panel 2). The categorical coefficient (also called
Hamming’s distance) and the unweighted pair group method with arithmetic
mean clustering method were run within BioNumerics. A cutoff value of 45%
similarity was applied to define clusters. It corresponds to differences at a max-
imum of 3 VNTRs out of 14. This is still empirical since there is no precise
knowledge about the VNTR evolutionary mechanism and speed, but it seems to
correctly define clusters when compared to those defined by other genotyping
methods. The minimum spanning tree was produced in BioNumerics, allowing
the creation of missing links. The circle size is proportional to the number of
isolates. A logarithmic scale was used when drawing branches.
The MLVA profiles and allele size ranges are available for comparison in the
MLVAbank for Bacterial Genotyping (http://mlva.u-psud.fr/ [Staphylococcus au-
reus database]).
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RESULTS
Selection of a VNTR panel. In a preliminary study performed in
2003, 14 VNTRs were selected by comparing the available se-
quenced genomes of strains Mu50, N315, MRSA252,
NCTC8325, MW2, and MSSA476 using the strain comparison
tool developed by Denoeud and Vergnaud (4) and available at
http://minisatellites.u-psud.fr/ (Microorganism Tandem Re-
peats database and Strain Comparison pages) (Table 1). They
were tested on a collection from the Pasteur Institute given to
us by Nevine El Sohl and previously typed by PFGE. These
initial results showed that MLVA could efficiently cluster
strains with similar pulsotypes (31). We then investigated the
informativeness and potential use of additional VNTRs de-
scribed in other studies. Most of the published primers did not
perfectly match the genome of the strains analyzed or they
were predicted by in silico analysis of thirteen sequenced ge-
nomes to amplify more than one locus. This is the case, for
instance, for the sdr locus in which the three highly informative
TRs present in genes sdrC, sdrD, and sdrE could not be am-
plified independently. In addition to the spa locus (SIRU21),
only SIRU01, SIRU13, and SIRU15 (15) and SAV920 and
SAV1078 (10) were retained and tested on a larger collection
of strains (data not shown). For SAV920 and SIRU01, lack of
amplification was observed in about 10% of strains, and there-
fore, these markers were not kept for a first-line MLVA
scheme. The selected set of loci comprises 14 VNTRs that are
present in all of the sequenced genomes, 6 of which correspond
to S. aureus repeat (STAR) elements (Sa0311, Sa0906, Sa1213,
TABLE 1. VNTRs used in this study
VNTR locus
and MLVA-14
panela
Gene or SIRU
where located
Size (bp)
of repeat
unit (U)f
No. of repeats
in Mu50
genome (N)f
Size (bp)
of PCR
product
in Mu50
(S)f
Oligonucleotideg Annealingtemp (°C)
Gene or region
amplified
Panel 1
Sa0122b spa 24 10 392 L, AGCAGTAGTGCCGTTTGCTT 60 spa
SIRU21 R, AAGACGATCCTTCAGTGAGCA
Sa0266c coa 81 6 630 L, TTGGATATGAAGCGAGACCA 60 coa
R, CTTCCGATTGTTCGATGCTT
Sa0311 55 3 272 L, AGGGTTAGAGCCCGAGACAT 60 STAR
R, CACGGGATTGGAACAGAAAT
Sa0704 67 4 380 L, CGCGCGTGAATCTCTTTTAT 60 Intergenic
R, AGTCCCATATCGTGCGTTAAA
Sa1132 63 6 532 L, CGTGCATAATGGCTTACGAA 60 SAV1078
R, AAGCAGCAGAAAAAGCTAAAGAA
Sa1194 67 7 524 L, AGTGCAAGCGGAAATTGAAG 60 Intergenic
R, ATCGTGAAAAAGCCCAAAAA
Sa1291 SIRU13 64 4 369 L, GGGGGAAATTCTAAGCAACC 60 Intergenic
R, CGAAATTTTCCACGTCGATT
Sa1729 56 5 499 L, TACTTAAAAATARGAATACATAATTAG 53 STAR
R, CAACAATAAATTACTTATTTGAAGTT
Sa1866 159 3 607 L, CTGTTTTGCAGCGTTTGCTA 60 SAV1738
R, GCAACTTGAAGAAACGGTTG
Sa2039 56 3 282 L, TTCGTTCTACCCCAACTTGC 60 STAR
R, GAGCCTGGGTCATAAATTCAA
Panel 2
Sa0906 56 3 864 L, CATGTATTCATGGGATTGCAGC 55 STAR
R, CAGATTTTCCTTCAACAATTATCAC
Sa1213 56 5 868 L, GGCTGATGCTAAAGTTGCATTAGA 55 STAR
R, GTGGCATGTTCTACAAACGTAAAC
Sa1425 58 4 630 L, TCGTTATTAAACTACGAATTCTCGATT 55 STAR
R, ATTTCGRGAATGATTCAATTCAATTTT
Sa1756d SIRU15 131 2 365 L, AATTATAGCATATTAGAGCCCCTTA 60 Intergenic
R, ACGTAAAGGTCGCGACAAAA
Other VNTRs
Sa2547 15 5 257 L, AAAGATGCTGAAAAGAAAGTGG 58 sbi
R, TGATCAATCGCACCTTTGTA
Sa387d SIRU1 55 2 299 L, CATGAGCAGTGCCTCCTTTA 55 Intergenic
R, CGCCTTGTATCTTAAATTTGTTG
Sa2821 SAV2654e 54 7 396 L, CTGAGTTTGAGTCTACTCCGC 58 SAV2654
SAV2655 R, CGTTTAAGAGCGAGAGTGTT
Sa964 SAV0920e 43 6 468 L, CAACACCATCATGTCCAATA 58 Intergenic
SAV0921 R, CAACCTGTTAATCCGATGTT
a Locus tags indicate the genomic localization in strain Mu50 (GenBank accession number AP009324) in kilobases.
b Primers are different from those in references 42 and 15.
c Primers are different from those in reference 37.
d SIRU1 and SIRU15 primers are those described in reference 15.
e Locus tag is from reference 10.
f U, N, and S were used to calculate the exact copy number of each allele as described in Materials and Methods.
g L, left; R, right.
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Sa1425, Sa1729, and Sa1866), a family of intergenic elements
whose copy numbers vary from 13 to 21 in individual strains
(3). The VNTR set contains four additional intergenic TRs
(Sa1756 [SIRU15], Sa0704, Sa1194, and Sa1291 [SIRU13])
and four TRs located inside the coding regions of the spa, coa,
SAV1078, and SAV1738 genes (corresponding to Sa0122,
Sa0266, Sa1132, and Sa1866, respectively). The MLVA scheme
was run with individual PCRs and agarose gel electrophoresis
of amplicons in this study, as shown in Fig. 1 for a subset of
VNTRs. The size of the amplicons can be easily estimated by
eye on agarose gels. For markers Sa0906 and Sa1213, the
absence of amplification was frequently observed when using
primers localized about 20 bp on each side of the TRs. There-
fore, primers inside the two genes flanking the STAR element
were selected, allowing correct amplification in all the strains.
A large number of alleles could be obtained for Sa0906, re-
flecting the complexity of the locus as confirmed by examina-
tion of the sequence (see “The structure of Sa0906” below).
This MLVA assay is perfectly reproducible, as attested by
the repeated use of Mu50 DNA as control, which always gave
the same result. In addition, the stability of the VNTRs in
cultured bacteria is demonstrated by the use of different
batches of Mu50 DNA and by the fact that the observed am-
plicon sizes are identical to those predicted by the genome
sequence.
Comparison of MLVA, MLST, and spa typing in 300 iso-
lates. To assess the informativeness of MLVA compared to
that of MLST and spa typing, we genotyped three complemen-
tary and well-referenced strain collections previously analyzed
by these two techniques and belonging to the major MLST
CCs. Overall, the efficiency of PCR amplification was excellent.
Only in three instances could no amplification be obtained,
which may be due to the absence or the mutation of the target
of one of the primers: Sa0311 failed to amplify two MLST
sequence type 398 (ST398) samples from nasal carriage, and
Sa1291 failed to amplify the ST8 sample NL33. The data were
used to perform a clustering analysis based upon the categor-
ical distance coefficient and unweighted pair group method
with arithmetic mean clustering method. With a cutoff value of
45%, 21 clusters were defined, two of which corresponded to a
single isolate (2 strains of nasal carriage, Laus167 of ST50 and
Laus325 of ST78) (see dendrogram in Fig. S1 in the supple-
mental material). These clusters correspond to CCs defined by
MLST and by spa typing together with the algorithm Based
Upon Repeat Pattern. Figure 2 shows a minimum spanning
tree which produces a more condensed representation of the
clustering and suggests relationships between the clusters. An
almost perfect correlation between the results of the different
techniques was observed, with the exception of a few isolates
which did not cluster by MLVA with strains of the same ST or
spa type. Strain NL33, spa typed as t701 that is associated with
CC8, is grouped with CC7, and Laus356, ST45 and spa type
t1081, is grouped with CC12, both with long branches. In
general, a much higher diversity was found with MLVA than
with MLST, particularly inside the major CCs, due to polymor-
phism at one or several VNTRs (Fig. 3). For example, the
groups of 19 ST8 and t008 isolates, 16 ST5 and t002 isolates,
and 18 ST30 and t012 isolates were each resolved into 12
MLVA genotypes. Thirteen ST45 t015 isolates were resolved
into seven MLVA genotypes (44). The diversity index of the
MLVA-14 assay is 0.9965 (95% CI, 0.9947 to 0.9984) (243
genotypes). In comparison, the diversity index of the MLST
assay with the same isolates (52 different STs) is 0.9314 (95%
CI, 0.9198 to 0.9431) and the diversity of the spa assay (127 spa
types) is 0.9802 (95% CI, 0.9755 to 0.9849).
In order to test whether the complete set of 14 VNTRs was
necessary to get a good resolution, clustering was performed
with different combinations of markers, and we found that very
satisfying clustering was already obtained with 10 VNTRs
(panel 1), excluding those occasionally showing very small al-
FIG. 1. Polymorphism of six VNTRs in 12 isolates (lanes numbered 1 to 12) as shown by agarose gel electrophoresis of PCR products. PCR
was performed on two groups of 6 unrelated isolates, and the products are migrated next to the DNA size marker (the sizes in base pairs are shown
on the left side of the first panel).
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leles (Sa0906, Sa1123, Sa1425, and Sa1756). The only incon-
sistency observed with panel 1 is the clustering of an ST121
(CC51) isolate with CC45 strains. Therefore, we propose to
use panel 1 to assign the isolates to a cluster and four addi-
tional markers (panel 2) for more informativeness. Panel 1
discriminates 215 genotypes with a diversity index of 0.9946
(95% CI, 0.9925 to 0.9967).
The structure of Sa0906. As explained above, VNTR Sa0906
is a TR present in a STAR element, which shows a complex
organization requiring the use of primers in the flanking cod-
ing regions for efficient PCR amplification (SAV0834 and
SAV0835) (Fig. 4). A large number of alleles was observed,
and in order to better assess their nature, these alleles were
sequenced. The basic organization of a STAR element is a
group of three sequences, or “boxes,” in the order B, C, A that
are 46 bp, 57 bp, and 97 bp long, respectively (24). Box C can
be tandemly repeated (Fig. 4, cat1). The shortest allele, corre-
sponding to a basic structure, was observed in only four isolates
from the present collection of strains (NL33 and a group of
nasal carriage isolates, Laus253, Laus369, and Laus292), all
localized in out-group positions. In isolates of CC45, the pres-
ence of a 21-bp duplication (Fig. 4, cat2) was observed and
different alleles were seen to possess one to four C sequences.
CC5 and CC8 isolates had an identical structure, with an in-
sertion within the box C repeats of the STAR element and
variations in copy number on both sides (Fig. 4, cat3). In
several other CCs (and in strain RF122), it seemed that a
deletion had removed part of this insertion (Fig. 4, cat4). An
artificial convention is proposed so that all the different alleles
and deletion combinations can be coded as in the case of an
ordinary TR variation (described in the support website at
http://minisatellites.u-psud.fr/MLVAnet/index.php?&largeur
-1680).
DISCUSSION
MLVA. We demonstrate in this study that the results of
MLVA genotyping of S. aureus are highly informative and
congruent with those of two other widely used techniques,
FIG. 2. Minimum spanning tree representation of the MLVA clus-
tering. The MLVA data for 311 isolates, including 10 reference strains,
was analyzed in BioNumerics. Each circle represents a genotype, and
the size is proportional to the number of isolates. Isolates in the main
MLST CCs are indicated by the different colors.
FIG. 3. Minimum spanning tree representation of the MLVA clustering of isolates belonging to CC8 and CC45. The size of each circle is
proportional to the number of isolates. Spa types are indicated inside circles and by using different colors. The dark circle means that more than
one spa type is present. The color codes for CC8 and CC45 are independent.
FIG. 4. Organization of the STAR element containing the Sa0906
VNTR. The diagram is drawn from the sequencing of PCR products
from isolates of different CCs. Arrows represent PCR primers; the
light gray bars represent sequence (“box”) A, the dark gray bars box B,
and the open bars box C. The black bars represent inserted sequences.
Cat, category.
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MLST and spa typing. MLVA provided better resolution and
was more congruent with the results of MLST than with those
of spa typing. VNTRs were previously used to genotype S.
aureus in a method called multilocus variable-number tandem-
repeat fingerprinting (MLVF) to reflect the fact that the data
are not interpreted in terms of repeat copy number at each
locus but simply used to compare multiple banding patterns as
is done with PFGE (21, 27, 38, 45). The discriminatory power
of MLVF is similar to that of PFGE, but the profiles are not
easily comparable between laboratories and this precludes the
constitution of international databases. The reproducibility of
MLVF might be also limited by the performance of 10-plex
PCRs. Other PCR-based genotyping techniques, such as re-
petitive sequence-based PCR, are satisfactory for determining
strain relatedness, but their informativeness is low and the data
are not suitable for population studies (47). Although MLVA
is a gel-based method (using either traditional gels or sophis-
ticated capillary electrophoresis equipment), it relies on coding
the results as a string of numbers. This, in contrast to all
fingerprinting methods, including PFGE and MLVF, makes
the resulting profiles highly reproducible and portable, like
MLST and spa typing.
In the present MLVA scheme, markers which could be eas-
ily analyzed using agarose gel electrophoresis were favored
(i.e., with a size difference between two alleles that is greater
than 5% of the amplicon size across the whole allele size
range). As such, the assay can be performed in a laboratory
equipped with simple molecular biology equipment. In addi-
tion, preliminary experiments showed that the assay can be
easily adapted to capillary electrophoresis. For instance, six
markers could be analyzed simultaneously on a Beckman
CEQ8000 apparatus in a multiplex PCR, using three fluoro-
phores and selecting VNTRs according to the allele size range
(see Fig. S2 in the supplemental material). Further develop-
ment of this procedure should allow the analysis of the com-
plete set of markers in two to three PCRs.
In addition to informativeness and portability, the cost issue
is also very important when choosing a genotyping technique,
particularly when thousands of isolates need to be investigated.
Based on the cost of consumables only, the cost of in-house
MLST typing for one sample (seven PCR amplifications and
seven sequencing reactions) was estimated to be $30, with an
initial start-up cost of $100,000 to $300,000 for equipment.
When sequencing is performed outside the laboratory, it
amounts at the very least to $50 per strain for sequencing costs
alone. The cost for consumables alone for MLVA with 14
VNTRs amounts to $10 per strain whether the analysis is done
with agarose gels or capillary electrophoresis, although the
later requires a considerably higher start-up investment and
expensive maintenance, whereas the former requires more
hands-on time.
Population structure. In recent years, MLST has provided a
clear view of the S. aureus population and its evolution, with
the definition of a number of well-defined CCs that are evolv-
ing, largely independently from each other, to such an extent
that some authors suggest giving species status to each CC
(46).
The collection of strains analyzed here covers the two groups
or clades identified by MLST analysis (2, 18). This is illustrated
in Fig. 5, using a minimum spanning tree representation and
FIG. 5. Minimum spanning tree representation of the MLST clustering, performed using the MLST sequence data. Missing links (empty
circles) and logarithmic branch length parameters were used.
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allowing the prediction of missing links. The phylogenetic re-
lationships observed by using MLVA data also separate the
isolates into two main groups (Fig. 2). The two clades are not
as sharply defined as those found by using MLST data, but the
main relationships between CCs are similar using either
MLVA or MLST. MLVA clearly allows the identification of
CCs and the emergence of new families, as shown here with
ST239 emerging from ST8, for example (33).
In the nasal carriage isolates, the clustering produced by
MLVA is very similar to that identified by eBURST analysis of
MLST data (39). In this previous work, ST942 and ST707 were
grouped by DLST, although, when grouped by MLST, they
differed by more than two mutations. This was also the case for
ST291 and ST398. The MLVA-14 assay, which investigates 14
loci throughout the genome, also groups these isolates, sug-
gesting a closely related origin of at least some part of their
genome. Their spa types are compatible with a recent common
origin. In the previous study mentioned above, amplified frag-
ment-length polymorphism analysis placed Laus356, an ST45
isolate with a spa type characteristic for CC45, with a long
branch next to the main CC45 cluster. By MLVA, this isolate
is positioned with a long branch near the CC12 cluster.
Among the 14 selected VNTRs, 6 are present in STAR
elements. The polymorphism of box C in STAR elements is
used in a typing protocol based on RFLP and PCR (32) and
contributes significantly to the present MLVA-14 assay. Addi-
tional polymorphism is provided by different rearrangements,
including the insertion or deletion of sequences which can be
further described upon sequencing. In particular, marker
Sa0906 shows at least four structures which appear to be of
phylogenetic value. Indeed, MLVA clustering places certain
strains in an ancestral position to specific clusters, for example,
NL33, a CC8 isolate from The Netherlands.
Antibiotic resistance. In the present collection, strains be-
longing to CC7, CC15, and CC25 were all MSSA, whereas both
MSSA and MRSA isolates were found intermixed in all the
other clusters. CC8 and CC5 isolates are mainly MRSA, as
previously observed. This is in agreement with the CCs ob-
served in typical MRSA and MSSA lineages worldwide (re-
viewed in reference 5).
CC45. We describe in CC45 an unusual polymorphism at
locus Sa0906, as well as in loci Sa1213 and Sa1425, with no or
only a fraction of one repeat (data not shown). In addition, this
CC also possesses only one copy of the repeat for loci Sa1132,
Sa1291, Sa2039, and Sa1756 (SIRU15). Among these VNTRs,
only locus Sa1132 is within a hypothetical protein-coding gene.
In addition, CC45 displays the highest level of spa polymor-
phism, apparently through loss of motifs, whereas the other
VNTRs show relatively less diversity (44). Therefore, we be-
lieve that in this CC, there is for some reason an important
level of recombination leading to deletion. We are presently
exploring the basis for this phenomenon. At the moment, there
is no complete sequenced genome available for a CC45 strain.
Conclusion. There is a need to expand investigations of
pathogenic bacterial populations on a worldwide scale. The
currently available data come from very few countries (36), and
the main typing method (MLST) has an insufficient discrimi-
natory power for epidemiological and shorter-term evolution-
ary studies, which is well exemplified by the study of Nubel et
al. (28). Single-nucleotide polymorphism typing might provide
an interesting alternative to MLST. However, in a highly clonal
species like S. aureus, the use of single-nucleotide polymor-
phisms is an inherently biased approach which will fail to
explore CCs not previously identified by other means. For
epidemiological studies, MLVA entails costs and time invest-
ment similar to those of spa typing while providing consider-
ably higher resolution. MLVA appears to be adapted to large-
scale investigations and, in addition, might give some insight
into the effects of DNA plasticity and recombination through
the analysis of the TR mechanism of instability. In contrast to
MLVF, in which VNTRs are used to produce a pattern,
MLVA investigates each locus independently. The MLVA-14
assay described here, comprising 10 loci in panel 1 and 4 loci in
panel 2, is highly discriminatory, cost efficient, reproducible,
and portable. The assay can be used in automated or more
manual protocols, as is best adapted to local conditions. If
necessary, additional VNTRs described in the literature (Table
1) could be added by taking advantage of the numerous avail-
able genome sequences to design new primer sets able to
amplify most if not all strains. In addition to the present col-
lection of strains, the MLVA-14 assay has been applied to
about 300 isolates from French patients with cystic fibrosis,
allowing a follow-up during chronic infection (H. Vu Thien, K.
Hormigos, G. Corbineau, B. Fauroux, H. Carvol, D.
Moissenet, G. Vergnaud, and C. Pourcel, unpublished data).
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